{
  "letters": 445924,
  "pages": 120,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Aptevo Therapeutics Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 13,
          "title": "Acquisition of Trubion Pharmaceuticals by Emergent BioSolutions",
          "data": [
            {
              "key": "Acquiring Company",
              "value": "Emergent BioSolutions Inc."
            },
            {
              "key": "Acquired Company",
              "value": "Trubion Pharmaceuticals, Inc."
            },
            {
              "key": "Acquisition Details",
              "value": "Trubion was acquired by Emergent BioSolutions before the development of the ADAPTIR platform technology."
            },
            {
              "key": "Patent Collaborators",
              "value": "Trubion and Wyeth Pharmaceuticals, Inc."
            },
            {
              "key": "Patent Regions Covered",
              "value": "United States, Australia, Israel, Japan, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa, South Korea, Vietnam."
            },
            {
              "key": "Pending Applications",
              "value": "Brazil, Canada, Norway."
            },
            {
              "key": "Estimated Patents Expiry Dates",
              "value": "2027-2036 for ADAPTIR patents, 2041 for ADAPTIR-FLEX patents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 15,
          "title": "FDA Clinical Trials Overview",
          "data": [
            {
              "key": "Clinical Trials Phases",
              "value": "Phase 1, Phase 2, Phase 3, Phase 4"
            },
            {
              "key": "Details on Phase 1 Trials",
              "value": "Test for safety, dose tolerance, absorption, bio-distribution, metabolism, excretion, etc."
            },
            {
              "key": "Purpose of Phase 2 Trials",
              "value": "Assess efficacy for specific indications, determine dose response, gather safety information."
            },
            {
              "key": "Phase 3 Trials Requirements",
              "value": "Typically require two trials for approval, generate definitive efficacy and safety evidence."
            },
            {
              "key": "Phase 4 Trials Purpose",
              "value": "Long-term safety information collection, additional data for specific populations."
            },
            {
              "key": "Expansion Cohorts Guidance",
              "value": "FDA guidance for early oncology trials to compress phases into one trial."
            },
            {
              "key": "BLA Support Data",
              "value": "May include patient experience and real-world evidence."
            },
            {
              "key": "Genetically Targeted Product Regulations",
              "value": "Allows reliance on previously developed data for similar technologies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 17,
          "title": "Marketing Approval - Biologics License Application",
          "data": [
            {
              "key": "Overview",
              "value": "All data obtained from a comprehensive development program, including research and product development, manufacturing, preclinical and clinical trials, labeling and related information are submitted in a biologics license application, or BLA, to the FDA."
            },
            {
              "key": "Application User Fees",
              "value": "Submission of a marketing application is subject to a substantial application user fee."
            },
            {
              "key": "Fee Waivers",
              "value": "Fee waivers or reductions are available in certain circumstances."
            },
            {
              "key": "FDA Review Period",
              "value": "The FDA has two months to review an application for its acceptability for filing."
            },
            {
              "key": "Review Types",
              "value": "Standard Review and Priority Review."
            },
            {
              "key": "PDUFA Dates",
              "value": "The FDA gives Priority Review status to product candidates that provide safe and effective therapies."
            },
            {
              "key": "Advisory Committee",
              "value": "The FDA may refer certain applications to an advisory committee."
            },
            {
              "key": "Compliance Inspections",
              "value": "Before approving a marketing application, the FDA typically will inspect the facility or facilities where the product is manufactured."
            },
            {
              "key": "CRL Process",
              "value": "The FDA may grant approval or deny the application through a complete response letter, or CRL."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 86,
          "title": "Lease and Financial Instruments Summary",
          "data": [
            {
              "key": "Lease Classification",
              "value": "Leases are classified as finance or operating leases at inception."
            },
            {
              "key": "Lease Liability Recognition",
              "value": "Recognized based on future minimum lease payments."
            },
            {
              "key": "Operating Lease Expense",
              "value": "Recognized on a straight-line basis."
            },
            {
              "key": "Finance Lease Expense",
              "value": "Consists of amortization and interest on lease liability."
            },
            {
              "key": "Fair Value Definition",
              "value": "Fair value is the exchange price in an orderly transaction."
            },
            {
              "key": "Debt Issuance Costs",
              "value": "Deferred and amortized to interest expense."
            },
            {
              "key": "Debt Modification Summary",
              "value": "Amended Credit Agreement with MidCap Financial."
            },
            {
              "key": "Amended Principal Reduction",
              "value": "Reduced principal from $25 million to $15 million."
            },
            {
              "key": "Unamortized Costs Treatment",
              "value": "Amortized over repayment term using effective interest method."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 90,
          "title": "Discontinued Operations and Deferred Payments Analysis",
          "data": [
            {
              "key": "Transaction Type",
              "value": "Divestiture of business components (sale of hyperimmune business and sale of Aptevo BioTherapeutics LLC)"
            },
            {
              "key": "Deferred Payment Details",
              "value": "For FY 2022, approximately $1.0M collected from Medexus related to IXINITY sales; for FY 2021, $0.5M was collected. The deferred payment rate increased from 2% to 5% of net sales as of June 30, 2022."
            },
            {
              "key": "Table Overview",
              "value": "The attached table compares deferred payments and discontinued operations for 2021-2022, showing an increase in deferred payments from Medexus and noting the absence of contingent consideration gains in 2022."
            },
            {
              "key": "Related Agreement",
              "value": "LLC Purchase Agreement with Medexus, which entitles future deferred payments and royalties."
            },
            {
              "key": "Additional Context",
              "value": "The document also addresses tax estimates, segment reporting, and an update on ASC 848 (Reference Rate Reform) with no material impact on the consolidated financial statements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 93,
          "title": "Amendment to Royalty Purchase Agreement",
          "data": [
            {
              "key": "Amendment date",
              "value": "June 7, 2022"
            },
            {
              "key": "Original Agreement",
              "value": "Royalty Purchase Agreement with HCR"
            },
            {
              "key": "Initial payment received",
              "value": "$35.0 million"
            },
            {
              "key": "Additional potential payments",
              "value": "up to $32.5 million based on sales milestones"
            },
            {
              "key": "Gain recognized due to amendment",
              "value": "$37.2 million"
            },
            {
              "key": "Compliance status",
              "value": "Regained full compliance with Nasdaq Listing Rule 5550(b)(1)"
            },
            {
              "key": "Changes in agreement",
              "value": "Foregone right to receive 50% of RUXIENCE incremental revenue"
            },
            {
              "key": "Liability nature",
              "value": "Recorded liability related to royalty proceeds"
            },
            {
              "key": "Transaction costs",
              "value": "$1.1 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 94,
          "title": "Royalty Revenue and Lease Amendments",
          "data": [
            {
              "key": "Description of Royalty Revenue",
              "value": "The royalty revenue included in the consolidated statements of operations reflects revenue recorded only prior to the second quarter of 2022 due to our Amendment to Royalty Purchase Agreement."
            },
            {
              "key": "2022 Milestone Payment Received",
              "value": "$2.5 million on February 28, 2023"
            },
            {
              "key": "Eligible Future Milestone Payment",
              "value": "$10 million based on achievement of sales milestones in 2023"
            },
            {
              "key": "Summary of Liability Changes for Royalties (2021-2022)",
              "value": "Shows the movement of liability related to sale of royalties, including notable items such as a gain from extinguishment of liability in 2022 of $(37,182) and proceeds from milestone payments of $9,500."
            },
            {
              "key": "Office Space Lease Amendment",
              "value": "Operating lease amended in March 2019 through April 2030, with options to extend and a recently removed termination option in exchange for $4.4 million lease liability and right-of-use asset."
            },
            {
              "key": "Variable Expense Recorded",
              "value": "Recorded $0.7 million and $0.8 million for the years ended December 31, 2022 and 2021, respectively."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Contribution Agreement, dated July 29, 2016, by and among Emergent BioSolutions Inc., Aptevo Therapeutics Inc., Aptevo Research and Development LLC and Aptevo BioTherapeutics LLC"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "August 2, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "2.2"
            },
            {
              "key": "Description",
              "value": "Separation and Distribution Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "August 2, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "2.3"
            },
            {
              "key": "Description",
              "value": "LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International Limited."
            },
            {
              "key": "Form",
              "value": "10-Q"
            },
            {
              "key": "Filing Date",
              "value": "November 13,2017"
            },
            {
              "key": "File No.",
              "value": "— 001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "2.4"
            },
            {
              "key": "Description",
              "value": "LLC Purchase Agreement by and among Aptevo Therapeutics Inc. and Medexus Pharma, Inc. dated February 28, 2020."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "March 2, 2020"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.1"
            },
            {
              "key": "Description",
              "value": "Amended_and_Restated_Certificate_of Incorporation of Aptevo Therapeutics Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "August 2, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.2"
            },
            {
              "key": "Description",
              "value": "Amended _and_ Restated By-laws of Aptevo Therapeutics Inc., as amended and restated on November 8, 2022."
            },
            {
              "key": "Form",
              "value": "10-Q"
            },
            {
              "key": "Filing Date",
              "value": "November 10,2022"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.3"
            },
            {
              "key": "Description",
              "value": "Certificate _of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "March 27, 2020"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.4"
            },
            {
              "key": "Description",
              "value": "Certificate of Designation of Series A Junior Participating Preferred Stock of Aptevo Therapeutics Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "November 9, 2020"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.5"
            },
            {
              "key": "Description",
              "value": "Amended and Restated Bylaws of Aptevo Therapeutics Inc."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "November 30, 2020"
            },
            {
              "key": "File No.",
              "value": "0001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.1"
            },
            {
              "key": "Description",
              "value": "Form of Common Stock Certificate"
            },
            {
              "key": "Form",
              "value": "10"
            },
            {
              "key": "Filing Date",
              "value": "June 29, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.2"
            },
            {
              "key": "Description",
              "value": "Registration Rights Agreement, dated _as of August 1, 2016, by and among Aptevo Therapeutics Inc. and certain of its stockholders"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "August 2, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.3"
            },
            {
              "key": "Description",
              "value": "Registration Rights Agreement, dated December 20, 2018, by_and tween Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "December 24,2018"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.4"
            },
            {
              "key": "Description",
              "value": "Rights Agreement, dated _as of November 8, 2020, by and between Aptevo Therapeutics Inc. and Broadridge Corporate Issuer Solutions, Inc., as rights agent"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "November 9, 2020"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 106,
          "title": "Exhibit and Filing Information",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.5"
            },
            {
              "key": "Description",
              "value": "Amendment No. | to Right Agreement, dated as of November 5, 2021, etween the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Filing Date",
              "value": "November 5, 2021"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 113,
          "title": "List of Subsidiaries",
          "data": [
            {
              "key": "Name of Subsidiary",
              "value": "Aptevo Research and Development LLC"
            },
            {
              "key": "Jurisdiction of Incorporation or Organization",
              "value": "Delaware"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 114,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "Aptevo Therapeutics Inc."
            },
            {
              "key": "Report Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Financial Statements",
              "value": "2022 consolidated financial statements"
            },
            {
              "key": "Registration Statements",
              "value": "Form S-8 (No. 333-265468), Form S-8 (No. 333-213108), Form S-8 (No. 333-219875), Form S-8 (No. 333-226717), Form S-3 (No. 333-251318)"
            },
            {
              "key": "Location",
              "value": "Seattle, Washington"
            },
            {
              "key": "Firm",
              "value": "Moss Adams LLP"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 24,
          "title": "Aptevo Therapeutics Information Disclosure",
          "data": [
            {
              "key": "Website",
              "value": "www.AptevoTherapeutics.com"
            },
            {
              "key": "SEC Filings",
              "value": "Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K"
            },
            {
              "key": "Disclosure Obligations",
              "value": "Disclosure obligations under Regulation FD"
            },
            {
              "key": "Website Usage",
              "value": "Means of disclosing material non-public information"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 103,
          "title": "Management’s Evaluation of Disclosure Controls and Procedures",
          "data": [
            {
              "key": "Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Management Participants",
              "value": "Chief Executive Officer, Chief Financial Officer"
            },
            {
              "key": "Evaluation Outcome",
              "value": "Effective"
            },
            {
              "key": "Criteria Used",
              "value": "Internal Control—Integrated Framework (2013)"
            },
            {
              "key": "Control Limitations",
              "value": "Inherent limitations in controls may prevent detection of misstatements. Projections are subject to future changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 110,
          "title": "Exhibit Index from SEC Filing – Aptevo Therapeutics Inc.",
          "data": [
            {
              "key": "Overview",
              "value": "This exhibit index from a financial filing contains various contractual documents including amendments to credit and security agreements, an Executive Transition Services Agreement and its amendment, a Purchase Agreement and a Registration Rights Agreement with Lincoln Park, as well as standard SEC certifications and inline XBRL documents. The presence of the Executive Transition Services Agreement and related certification documents suggest aspects of executive or leadership transition."
            },
            {
              "key": "Key Exhibits",
              "value": "• Exhibit 0.42: Executive Transition Services Agreement (10-Q, Filed November 12, 2021); • Exhibit 0.43: Amendment to Executive Transition Services Agreement (10-Q, Filed November 12, 2021)"
            },
            {
              "key": "Additional Documents",
              "value": "Amendments to Credit and Security Agreements (Exhibits 0.40 and 0.41), Purchase Agreement (Exhibit 0.44), Registration Rights Agreement (Exhibit 0.45), Subsidiaries list (Exhibit 21.1), Independent CPA consent (Exhibit 23.1), and routine SEC certifications (Exhibits 31.1, 31.2, 32.1*, 32.2*) plus Inline XBRL documents."
            },
            {
              "key": "Filing Reference",
              "value": "SEC filings include 8-K and 10-Q forms with File No. 001-37746 and filing dates in 2021-2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 112,
          "title": "Corporate Leadership Signatures",
          "data": [
            {
              "key": "Name",
              "value": "Marvin L. White"
            },
            {
              "key": "Position",
              "value": "President, Chief Executive Officer and Director Executive"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Daphne Taylor"
            },
            {
              "key": "Position",
              "value": "Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "John E. Niederhuber, M.D."
            },
            {
              "key": "Position",
              "value": "Chairman of the Board of Directors"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Daniel J. Abdun-Nabi"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Grady Grant, II"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Zsolt Harsanyi, Ph.D."
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Barbara Lopez Kunz"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 115,
          "title": "Certification Pursuant to Rules 13a-14(a) and 15d-14(a) Under the Securities Exchange Act of 1934",
          "data": [
            {
              "key": "Certified By",
              "value": "Marvin L. White"
            },
            {
              "key": "Position",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Date",
              "value": "March 30, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Certification Pursuant to Rules 13a-14 and 15d-14 Under the Securities Exchange Act of 1934",
          "data": [
            {
              "key": "Officer Name",
              "value": "Daphne Taylor"
            },
            {
              "key": "Title",
              "value": "Senior Vice President and Chief Financial Officer"
            },
            {
              "key": "Certification Date",
              "value": "March 30, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 117,
          "title": "Certification Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934",
          "data": [
            {
              "key": "Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Name",
              "value": "Marvin L. White"
            },
            {
              "key": "Position",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Company",
              "value": "Aptevo Therapeutics Inc."
            },
            {
              "key": "Report Period Ending",
              "value": "December 31, 2022"
            },
            {
              "key": "Compliance Certification",
              "value": "The Report fully complies with requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934."
            },
            {
              "key": "Fair Presentation Certification",
              "value": "The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 118,
          "title": "Certification Pursuant to Rule 13a-14(b)",
          "data": [
            {
              "key": "Company Name",
              "value": "Aptevo Therapeutics Inc."
            },
            {
              "key": "Report Type",
              "value": "Form 10-K"
            },
            {
              "key": "Period Ending",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "March 30, 2023"
            },
            {
              "key": "Signer Name",
              "value": "Daphne Taylor"
            },
            {
              "key": "Signer Title",
              "value": "Senior Vice President and Chief Financial Officer"
            },
            {
              "key": "Compliance Statement",
              "value": "The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934."
            },
            {
              "key": "Fair Presentation Statement",
              "value": "The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 9,
          "title": "Overview of Cohorts and Study Design",
          "data": [
            {
              "key": "Phase of Study",
              "value": "Phase 1b"
            },
            {
              "key": "Total Patients Planned",
              "value": "90"
            },
            {
              "key": "Total Patients Enrolled",
              "value": "44"
            },
            {
              "key": "Cohorts",
              "value": "5"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 9,
          "title": "Clinical Trial Cohort Treatment Protocol",
          "data": [
            {
              "key": "Cohort 1",
              "value": "1st or 2nd early relapse or primary refractory disease"
            },
            {
              "key": "Cohort 2",
              "value": "Frontline or 1st relapse or primary refractory disease"
            },
            {
              "key": "Cohort 3",
              "value": "Consolidation after frontline or 2nd line or primary refractory disease"
            },
            {
              "key": "Cohort 4",
              "value": "MRD+: 1st remission"
            },
            {
              "key": "Cohort 5",
              "value": "MRD+: 2nd remission"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 9,
          "title": "Table: Patient Response Rate to APVO436 Treatment",
          "data": [
            {
              "key": "Total Enrollment",
              "value": "56 patients"
            },
            {
              "key": "Evaluable for Response Assessment",
              "value": "42 patients"
            },
            {
              "key": "Results Summary",
              "value": "Venetoclax naive cohort receiving APVO436 + Ven/Aza showed the highest CBR (91%) and CR/CRi rate (73%)."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 71,
          "title": "Equity Distribution and Purchase Agreements Overview",
          "data": [
            {
              "key": "Deferred Payment Rate Increase",
              "value": "from 2% to 5% of net sales as of June 30, 2022"
            },
            {
              "key": "Deferred Payments Received",
              "value": "$1.0 million from Medexus related to IXINITY sales for the year ended December 31, 2022"
            },
            {
              "key": "Equity Distribution Agreement Date",
              "value": "December 14, 2020"
            },
            {
              "key": "Total Offering Price under Equity Distribution Agreement",
              "value": "up to $50 million"
            },
            {
              "key": "Shares Issued under Equity Distribution Agreement",
              "value": "1,452,065 shares at an average price of $4.92"
            },
            {
              "key": "Proceeds from Issuance of Shares",
              "value": "$7.0 million"
            },
            {
              "key": "Equity Distribution Agreement Issuance in 2021",
              "value": "0 shares"
            },
            {
              "key": "Registration Statement Filed",
              "value": "December 14, 2020"
            },
            {
              "key": "Total Amount in Registration Statement",
              "value": "up to $200 million"
            },
            {
              "key": "Market Value Limitation",
              "value": "Cannot exceed one-third of aggregate market value held by non-affiliates in any 12-month period while below $75 million"
            },
            {
              "key": "Lincoln Park Purchase Agreement Date",
              "value": "February 16, 2022"
            },
            {
              "key": "Lincoln Park Commitment Amount",
              "value": "up to $35.0 million over a 36-month period"
            },
            {
              "key": "Initial Fee Shares Issued to Lincoln Park",
              "value": "99,276 shares for no cash consideration"
            },
            {
              "key": "Sales Rights to Lincoln Park",
              "value": "Dependent on market conditions and the Company's discretion."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 76,
          "title": "Stock-Based Compensation Details and Clinical Study Expenses",
          "data": [
            {
              "key": "Compensation Measurement",
              "value": "Recognition of compensation expense for RSUs and stock options granted to employees and directors under ASC 718 based on fair value at the date of grant."
            },
            {
              "key": "Valuation Model",
              "value": "Black-Scholes option pricing model using inputs such as expected term, volatility, risk-free interest rate, and zero expected dividend yield."
            },
            {
              "key": "Expense Recognition",
              "value": "Stock-based compensation expense recognized on a straight-line basis over the vesting period."
            },
            {
              "key": "Forfeiture Rate",
              "value": "Estimated based on historical forfeiture experience, employee turnover, and expectations of future option exercise behavior."
            },
            {
              "key": "Clinical Study Expenses",
              "value": "Accrual estimates depend on the number of enrolled patient visits per site and data provided by CROs, with adjustments as necessary."
            },
            {
              "key": "Contract Milestones",
              "value": "Referenced in relation to achieving targets that affect accruals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 89,
          "title": "General and Administrative Expenses, Stock-Based Compensation, and Income Taxes",
          "data": [
            {
              "key": "General and Administrative Expenses",
              "value": "Expenses primarily consist of personnel-related costs and professional fees supporting various corporate functions such as executive, business development, finance, accounting, IT, legal, and HR. Includes facility costs not captured in R&D expenses."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "Recognition and measurement of compensation expense for RSUs and stock options granted to employees and directors. Uses the Black-Scholes model with inputs including expected term, volatility, risk-free interest rate, and a zero expected dividend yield; expense is recognized on a straight-line basis over the vesting period."
            },
            {
              "key": "Income Taxes",
              "value": "Accounts for income taxes using the liability method. Deferred tax assets and liabilities are measured using enacted tax rates with adjustments via valuation allowances based on the likelihood of realization in future taxable income."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 97,
          "title": "Equity Distribution Agreement with Piper Sandler",
          "data": [
            {
              "key": "Agreement Date",
              "value": "December 14, 2020"
            },
            {
              "key": "Aggregate Offering Price",
              "value": "up to $50.0 million"
            },
            {
              "key": "Shares Issued in 2022",
              "value": "1,452,065 shares"
            },
            {
              "key": "Average Share Price in 2022",
              "value": "$4.92"
            },
            {
              "key": "Proceeds from Issuance in 2022",
              "value": "$7.0 million"
            },
            {
              "key": "Shares Issued in 2021",
              "value": "0"
            },
            {
              "key": "Replacement Agreement",
              "value": "2017 program replaced by 2020 agreement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 97,
          "title": "Lincoln Park Purchase Agreement",
          "data": [
            {
              "key": "Agreement Date",
              "value": "February 16, 2022"
            },
            {
              "key": "Commitment Amount",
              "value": "up to $35.0 million"
            },
            {
              "key": "Initial Shares Issued",
              "value": "99,276 shares for no cash"
            },
            {
              "key": "Cash Proceeds from 2018 Agreement",
              "value": "$10.2 million"
            },
            {
              "key": "Shares Issued in 2021",
              "value": "407,047 shares"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 97,
          "title": "Rights Plan",
          "data": [
            {
              "key": "Approval Date",
              "value": "November 8, 2020"
            },
            {
              "key": "Rights per Share",
              "value": "one preferred share purchase right"
            },
            {
              "key": "Exercise Price",
              "value": "$400.00"
            },
            {
              "key": "Expiration Date Extension",
              "value": "November 4, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 97,
          "title": "2016 Stock Incentive Plan",
          "data": [
            {
              "key": "Adoption Date",
              "value": "August 1, 2016"
            },
            {
              "key": "Total Shares Authorized",
              "value": "0.2 million shares"
            },
            {
              "key": "Increased Shares in 2017",
              "value": "0.1 million shares"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Stock-based Compensation Expense by Category",
          "data": [
            {
              "key": "category",
              "value": "Research and development"
            },
            {
              "key": "2022",
              "value": "196"
            },
            {
              "key": "2021",
              "value": "510"
            },
            {
              "key": "category",
              "value": "General and administrative"
            },
            {
              "key": "2022",
              "value": "1606"
            },
            {
              "key": "2021",
              "value": "1133"
            },
            {
              "key": "category",
              "value": "Total stock-based compensation expense"
            },
            {
              "key": "2022",
              "value": "1802"
            },
            {
              "key": "2021",
              "value": "1643"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Stock Options Valuation Assumptions",
          "data": [
            {
              "key": "Expected dividend yield",
              "value": "0.00%"
            },
            {
              "key": "Expected volatility",
              "value": "106.24%"
            },
            {
              "key": "Risk-free interest rate",
              "value": "1.71%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 99,
          "title": "Stock Option Activity",
          "data": [
            {
              "key": "Outstanding at December 31, 2021",
              "value": "334,412"
            },
            {
              "key": "Granted",
              "value": "69,588"
            },
            {
              "key": "Exercised",
              "value": "(85)"
            },
            {
              "key": "Forfeited",
              "value": "(39,649)"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "364,266"
            },
            {
              "key": "Exercisable at December 31, 2022",
              "value": "187,838"
            },
            {
              "key": "Vested and expected to vest at December 31, 2022",
              "value": "321,078"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 99,
          "title": "Stock Units Activity and Fair Value Summary",
          "data": [
            {
              "key": "Outstanding at December 31, 2021",
              "value": "56810"
            },
            {
              "key": "Granted",
              "value": "199604"
            },
            {
              "key": "Vested",
              "value": "-17903"
            },
            {
              "key": "Forfeited",
              "value": "-14736"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "223715"
            },
            {
              "key": "Expected to Vest",
              "value": "223715"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 104,
          "title": "Executive Compensation Overview",
          "data": [
            {
              "key": "Information Source",
              "value": "Proxy Statement"
            },
            {
              "key": "Headings",
              "value": "Executive Compensation, Director Compensation"
            },
            {
              "key": "Next Filing Date",
              "value": "Not later than 120 days after December 31, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "4.6"
            },
            {
              "key": "Description",
              "value": "Amendment No. 2 to Rights Agreement, dated as of November 4, 2022, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "_ Exhibit",
              "value": "41"
            },
            {
              "key": "Filing Date",
              "value": "November 4, 2022"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "AT"
            },
            {
              "key": "Description",
              "value": "Description of Capital Stock of Aptevo Therapeutics"
            },
            {
              "key": "Form",
              "value": ""
            },
            {
              "key": "_ Exhibit",
              "value": "4.5"
            },
            {
              "key": "Filing Date",
              "value": "March 31, 2021"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "48"
            },
            {
              "key": "Description",
              "value": "Agreement to Terminate Registration Rights Agreement between the Company and Intervac L.L.C. and BioVac L.L.C."
            },
            {
              "key": "Form",
              "value": "10-K"
            },
            {
              "key": "_ Exhibit",
              "value": "4.1"
            },
            {
              "key": "Filing Date",
              "value": "March 24, 2022"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 111,
          "title": "Cover Page Interactive Data File",
          "data": [
            {
              "key": "Description",
              "value": "Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101) * Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing."
            },
            {
              "key": "Confidential Treatment",
              "value": "Confidential treatment granted from the Securities and Exchange Commission as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission."
            },
            {
              "key": "Management Contract",
              "value": "C Management contract or compensatory plan."
            },
            {
              "key": "Omitted Schedules",
              "value": "+ Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Aptevo will furnish copies of any such schedules to the Securities and Exchange Commission upon request."
            },
            {
              "key": "Item 16 Summary",
              "value": "We have chosen not to include the summary permitted by this Item 16."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 2,
          "title": "ADAPTIR vs ADAPTIR-FLEX Technology Comparison",
          "data": [
            {
              "key": "Drug Targeting",
              "value": "ADAPTIR: Bind up to two targets; ADAPTIR-FLEX: Bind up to four targets"
            },
            {
              "key": "Genetic and Structural Format",
              "value": "ADAPTIR: Single gene that assembles into an antibody backbone homodimer; ADAPTIR-FLEX: Two genes that assemble into a heterodimer based on a mutated antibody backbone"
            },
            {
              "key": "Half-life",
              "value": "ADAPTIR: Demonstrated antibody-like half-life; ADAPTIR-FLEX: Antibody-like half-life in mice"
            },
            {
              "key": "Effector Function",
              "value": "ADAPTIR: Fc mutations may be utilized to eliminate binding; ADAPTIR-FLEX: Can be engineered to enhance effector function via Fc Gamma Receptors"
            },
            {
              "key": "Manufacturing",
              "value": "Both platforms employ antibody-like manufacturing processes"
            },
            {
              "key": "Current Pipeline Candidates",
              "value": "ADAPTIR: APV0436 (CD123 x CD3), ALG.APV-527 (41BB x 5T4), APV0603 (41BB x OX40), APVO711 (PD-L1 x CD40); ADAPTIR-FLEX: APV0442 (PSMA x CD3)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 4,
          "title": "STRATEGY and Product Development Pipeline",
          "data": [
            {
              "key": "Lead Clinical Stage Candidate",
              "value": "APVO436 is being advanced through clinical development with plans to initiate a Phase 2 trial in the second half of 2023, evaluating its efficacy in combination with Venetoclax and Azacitidine for acute myelogenous leukemia (AML)."
            },
            {
              "key": "Solid Tumor Candidate",
              "value": "ALG.APV-527, developed in partnership with Alligator Bioscience, is under investigation in a first-in-human Phase I trial targeting 4-1BB and 5T4 for multiple solid tumor indications, with ongoing patient enrollment."
            },
            {
              "key": "Preclinical Candidates",
              "value": "Candidates including APVO603 (targeting 4-1BB and OX40), APVO442 (targeting PSMA and CD3), and APVO711 (a dual mechanism bispecific antibody that blocks PD-1/PD-L1 while stimulating CD40) are progressing through preclinical and IND-enabling studies. A provisional patent for APVO711 was filed in January 2023."
            },
            {
              "key": "Platform Technology",
              "value": "The strategy emphasizes the use of innovative platforms—ADAPTIR and ADAPTIR-FLEX—for developing novel bispecific and multispecific protein immunotherapies, with plans to expand the product pipeline and establish collaborative partnerships."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 75,
          "title": "Commitments for Research Services and R&D Expenses",
          "data": [
            {
              "key": "vendor_commitments",
              "value": "Obligations under vendor contracts to purchase research services and other purchase commitments with vendors."
            },
            {
              "key": "services_agreements",
              "value": "Enter into services agreements with contract research organizations, contract manufacturing organizations, and other third parties with termination terms based on notice and timing."
            },
            {
              "key": "critical_accounting_policies",
              "value": "Discussion of critical accounting policies and significant judgments/estimates used in preparing consolidated financial statements under GAAP."
            },
            {
              "key": "research_and_development_expenses",
              "value": "Expenses are recognized as incurred and primarily include internal labor costs, fees paid to external service providers, material costs for clinical trials and R&D, with many functions performed by third-party CROs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 91,
          "title": "Note 3: Collaboration Agreements & Related Financial Disclosures",
          "data": [
            {
              "key": "Collaboration Agreement Date",
              "value": "July 20, 2017"
            },
            {
              "key": "Partner",
              "value": "Alligator Bioscience AB"
            },
            {
              "key": "Subsidiary Involved",
              "value": "Aptevo Research and Development LLC (Aptevo R&D)"
            },
            {
              "key": "Product Candidate",
              "value": "ALG.APV-527 (lead bispecific antibody targeting 4-1BB and 5T4)"
            },
            {
              "key": "R&D Expense 2022",
              "value": "$1.7 million"
            },
            {
              "key": "R&D Expense 2021",
              "value": "$0.1 million"
            },
            {
              "key": "Cash, Cash Equivalents, and Restricted Cash Total 2022",
              "value": "$22,635,000"
            },
            {
              "key": "Cash, Cash Equivalents, and Restricted Cash Total 2021",
              "value": "$46,303,000"
            },
            {
              "key": "Fair Value Note",
              "value": "Money market funds approximate fair value; no Level 2 or Level 3 assets/liabilities as of December 31, 2022 and 2021"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 5,
          "title": "Platform Technology ADAPTIR and ADAPTIR-FLEX Platform Technologies",
          "data": [
            {
              "key": "Platform Name",
              "value": "ADAPTIR and ADAPTIR-FLEX"
            },
            {
              "key": "Description",
              "value": "The ADAPTIR and ADAPTIR-FLEX platforms are designed to produce monospecific, bispecific, and multi-specific immunotherapeutic proteins. These antibody-like molecules can be modulated to add or remove immune functions while maintaining advantages such as stability, size, and extended half-life."
            },
            {
              "key": "Therapeutic Areas",
              "value": "Oncology (main focus) and potential applications in inflammatory diseases"
            },
            {
              "key": "Mechanism",
              "value": "Utilizes customizable polypeptide chains with an antibody Fc region. The platform allows modifications to the Fc region to enhance or disable effector functions, improving properties like immune response engagement and half-life extension via FcRn recycling."
            },
            {
              "key": "Advantages",
              "value": "Manufacturing efficiencies and the ability to precisely tailor therapeutic functions similar to monoclonal antibodies while providing the flexibility to eliminate or incorporate specific activities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 6,
          "title": "ADAPTIR Platform Technology – Bispecific and Monospecific Protein Therapeutics",
          "data": [
            {
              "key": "Platform Description",
              "value": "The ADAPTIR platform technology enables the design of both monospecific and bispecific bi-valent protein therapeutics."
            },
            {
              "key": "Bispecific Molecules",
              "value": "Bispecific ADAPTIR molecules have two customized target binding domains at the ends of the Fc region, unlike the monospecific ones which only have a single binding domain."
            },
            {
              "key": "RTCC Mechanism",
              "value": "The RTCC ADAPTIR molecules redirect T cell cytotoxicity by binding the common T cell component CD3 via one binding domain while engaging a specific tumor antigen with the other, activating T cells to kill tumor cells."
            },
            {
              "key": "Image Details",
              "value": "The accompanying diagram compares antibody structures: both types feature a scFv or Protein Domain 1 at the top linked to a mutated IgG-Fc region with 'No ADCC', 'No CDC', and 'FcRn binding'. The bispecific structure includes an additional binding domain connected by a linker."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 7,
          "title": "ADAPTIR-FLEX Platform Technology for Advanced Immunotherapeutics",
          "data": [
            {
              "key": "platform",
              "value": "ADAPTIR-FLEX"
            },
            {
              "key": "technology_description",
              "value": "Our ADAPTIR-FLEX platform extends ADAPTIR technology to create protein therapeutics with varied specificity, valency, and potentially new modes of action."
            },
            {
              "key": "mechanism",
              "value": "Composed of two different polypeptides forming a heterodimer via modified Fc regions, enabling customizable binding domains."
            },
            {
              "key": "therapeutic_application",
              "value": "Immuno-oncology therapeutics, with applications such as redirected T cell cytotoxicity (RTCC), modulation of immunostimulatory/inhibitory receptors, and targeted cytokine delivery."
            },
            {
              "key": "example_candidate",
              "value": "APVO436, an RTCC ADAPTIR bispecific that binds CD123, demonstrating potency at low doses with reduced cytokine release."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Products",
              "value": "APV0436 CD3 x CD123; ALG.APV-527 4-1BB x 5T4; APV0603 4-1BB x OX40; APV0442 PSMA x CD3; APV0711 PD-L1 x CD40"
            },
            {
              "key": "Technologies",
              "value": "Redirected T cell Cytotoxicity (RTCC); T cell Co-Stimulation; Dual T cell Co-Stimulation; RTCC; Checkpoint Inhibitor & Stimulator of Antigen Presenting Cells"
            },
            {
              "key": "Indications",
              "value": "AML/MDS; Multiple Solid Tumors; Multiple Solid Tumors; Prostate Cancer; Multiple Solid Tumors"
            },
            {
              "key": "Stages",
              "value": "Phase I; Pre-Clinical; Pre-Clinical; Pre-Clinical; Pre-Clinical"
            },
            {
              "key": "Next Milestones",
              "value": "New expansion phase data reported at ASH, Phase 2 program initiation in 2H23; IND cleared, Phase 1 trial initiation 1Q23; Ongoing IND-enabling studies; Ongoing pre-clinical studies; Initiated pre-clinical studies"
            },
            {
              "key": "Metadata Categories",
              "value": "Hematologic Cancers, Solid Tumor Cancers"
            },
            {
              "key": "Development Stages",
              "value": "Pre-Clinical, Phase I, Phase II, Phase III"
            },
            {
              "key": "Partnership Note",
              "value": "Partnered with Alligator Bioscience"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Product Candidates - APVO436 Overview",
          "data": [
            {
              "key": "Description",
              "value": "APVO436 is a bispecific ADAPTIR designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells and leukemic stem cells."
            },
            {
              "key": "Clinical Trial",
              "value": "Completed enrollment in a multi-center, multi-cohort Phase 1b trial (APVO436-5001), evaluating use as monotherapy and in combination with standard-of-care therapies."
            },
            {
              "key": "Safety & Engineering",
              "value": "Engineered using proprietary ADAPTIR platform to reduce likelihood and severity of cytokine release syndrome (CRS)."
            },
            {
              "key": "Regulatory Status",
              "value": "Received orphan drug designation from the FDA for the treatment of acute myelogenous leukemia."
            },
            {
              "key": "Data Presentation",
              "value": "Preliminary data presented at the 64th American Society of Hematology (ASH) annual meeting on December 11, 2022."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 84,
          "title": "Nature of Business and Significant Accounting Policies",
          "data": [
            {
              "key": "Company Name",
              "value": "Aptevo Therapeutics Inc."
            },
            {
              "key": "Business Focus",
              "value": "clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer"
            },
            {
              "key": "Lead Candidates",
              "value": "APVO436, ALG.APV-527"
            },
            {
              "key": "Preclinical Candidates",
              "value": "APVO603, APVO711, APVO442"
            },
            {
              "key": "Net Income (2022)",
              "value": "$8.0 million"
            },
            {
              "key": "Accumulated Deficit (2022)",
              "value": "$206.0 million"
            },
            {
              "key": "Net Cash Used in Operating Activities (2022)",
              "value": "$21.0 million"
            },
            {
              "key": "Capital Resources",
              "value": "cash resources, milestone payments related to Royalty Purchase Agreement, funds from Purchase Agreement with Lincoln Park, and other potential funding sources"
            },
            {
              "key": "Future Funding Needs",
              "value": "may need additional funds to support operating and capital needs"
            },
            {
              "key": "Risks",
              "value": "changes in strategy, spending plans, macroeconomic conditions, and other uncertainties affecting capital resources"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 92,
          "title": "Property and Equipment Summary",
          "data": [
            {
              "key": "Leasehold improvements (2022)",
              "value": "$2,228"
            },
            {
              "key": "Furniture and equipment (2022)",
              "value": "$12,260"
            },
            {
              "key": "Property and equipment, gross (2022)",
              "value": "$14,488"
            },
            {
              "key": "Less: Accumulated depreciation (2022)",
              "value": "-$13,026"
            },
            {
              "key": "Total property and equipment, net (2022)",
              "value": "$1,462"
            },
            {
              "key": "Leasehold improvements (2021)",
              "value": "$2,228"
            },
            {
              "key": "Furniture and equipment (2021)",
              "value": "$12,430"
            },
            {
              "key": "Property and equipment, gross (2021)",
              "value": "$14,658"
            },
            {
              "key": "Less: Accumulated depreciation (2021)",
              "value": "-$12,279"
            },
            {
              "key": "Total property and equipment, net (2021)",
              "value": "$2,379"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Operating Lease Cost Summary",
          "data": [
            {
              "key": "Operating lease cost",
              "value": "$1,277,000 in 2022"
            },
            {
              "key": "Total lease cost",
              "value": "$1,277,000 in 2022"
            },
            {
              "key": "Operating lease cost",
              "value": "$1,556,000 in 2021"
            },
            {
              "key": "Total lease cost",
              "value": "$1,556,000 in 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Right-of-Use Assets Comparison",
          "data": [
            {
              "key": "Seattle office lease, including amendment",
              "value": "$5,303,000 in 2022"
            },
            {
              "key": "Total right-of-use assets",
              "value": "$5,303,000 in 2022"
            },
            {
              "key": "Seattle office lease, including amendment",
              "value": "$1,577,000 in 2021"
            },
            {
              "key": "Total right-of-use assets",
              "value": "$1,584,000 in 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Operating Lease Expenses Comparison",
          "data": [
            {
              "key": "For operating leases",
              "value": "$895,000 in 2022"
            },
            {
              "key": "For operating leases",
              "value": "$1,387,000 in 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Future Minimum Lease Payments Schedule",
          "data": [
            {
              "key": "2023",
              "value": "$1,147"
            },
            {
              "key": "2024",
              "value": "$1,376"
            },
            {
              "key": "2025",
              "value": "$1,376"
            },
            {
              "key": "2026 and beyond",
              "value": "$5,963"
            },
            {
              "key": "Total future minimum lease payments",
              "value": "$9,862"
            },
            {
              "key": "Less: imputed interest",
              "value": "-$3,402"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.14"
            },
            {
              "key": "Description",
              "value": "Seattle Office Lease Amendment, dated July 17, 2012"
            },
            {
              "key": "Form",
              "value": "0"
            },
            {
              "key": "Exhibit",
              "value": "0.18"
            },
            {
              "key": "Filing Date",
              "value": "April 15, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.15"
            },
            {
              "key": "Description",
              "value": "Seventh Amendment to Seattle Office Lease, dated December 5, 2014"
            },
            {
              "key": "Form",
              "value": "0"
            },
            {
              "key": "Exhibit",
              "value": "0.19"
            },
            {
              "key": "Filing Date",
              "value": "April 15, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.16"
            },
            {
              "key": "Description",
              "value": "License_and Co-Development Agreement, dated_as of August 19, 2014, by and between Emergent Product Development Seattle, LLC"
            },
            {
              "key": "Form",
              "value": "10"
            },
            {
              "key": "Exhibit",
              "value": "0.20"
            },
            {
              "key": "Filing Date",
              "value": "June 29, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.17"
            },
            {
              "key": "Description",
              "value": "and MorphoSys AG, or the MorphoSys Collaboration Agreement First Amendment to MorphoSys Collaboration Agreement, dated June 19, 2015"
            },
            {
              "key": "Form",
              "value": "10"
            },
            {
              "key": "Exhibit",
              "value": "0.21"
            },
            {
              "key": "Filing Date",
              "value": "April 15, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.18"
            },
            {
              "key": "Description",
              "value": "Second Amendment _to MorphoSys Collaboration Agreement, dated December 7, 2015"
            },
            {
              "key": "Form",
              "value": "10"
            },
            {
              "key": "Exhibit",
              "value": "0.22"
            },
            {
              "key": "Filing Date",
              "value": "April 15, 2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.19"
            },
            {
              "key": "Description",
              "value": "Third Amendment _to MorphoSys Collaboration Agreement, dated December 12, 2016"
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Exhibit",
              "value": "10.1"
            },
            {
              "key": "Filing Date",
              "value": "December 15,2016"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.20"
            },
            {
              "key": "Description",
              "value": "Fourth Amendment MorphoSys Collaboration Agreement, dated June 19, 2017."
            },
            {
              "key": "Form",
              "value": "10"
            },
            {
              "key": "Exhibit",
              "value": "10.3"
            },
            {
              "key": "Filing Date",
              "value": "August 10, 2017"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.21"
            },
            {
              "key": "Description",
              "value": "Equity Distribution Agreement, dated November 9, 2017, between Aptevo Therapeutics, Inc. and Piper Jaffray and Company LLC."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Exhibit",
              "value": "1.1"
            },
            {
              "key": "Filing Date",
              "value": "November 9, 2017"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.22"
            },
            {
              "key": "Description",
              "value": "Collaboration and Option Agreement, dated as of July 20, 2017, by and between Aptevo Research and Development LLC, and Alligator Bioscience AB."
            },
            {
              "key": "Form",
              "value": "10-Q"
            },
            {
              "key": "Exhibit",
              "value": "10.2"
            },
            {
              "key": "Filing Date",
              "value": "November 13,2017"
            },
            {
              "key": "File No.",
              "value": "—_ 001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.23"
            },
            {
              "key": "Description",
              "value": "Amendment No. 3 to Credit and Security Agreement, dated _as of February 23, 2018, by and among Aptevo Therapeutics Inc. and certain of its subsidiaries and Midcap Financial Trust."
            },
            {
              "key": "Form",
              "value": "10-K"
            },
            {
              "key": "Exhibit",
              "value": "10.38"
            },
            {
              "key": "Filing Date",
              "value": "March 13, 2018"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.24"
            },
            {
              "key": "Description",
              "value": "Aptevo Therapeutics Inc. 2018 Stock Incentive Plan."
            },
            {
              "key": "Form",
              "value": "0-Q"
            },
            {
              "key": "Exhibit",
              "value": "0.1"
            },
            {
              "key": "Filing Date",
              "value": "August 9, 2018"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.25"
            },
            {
              "key": "Description",
              "value": "Aptevo Therapeutics Inc. Non-Statutory Stock Option Agreement."
            },
            {
              "key": "Form",
              "value": "0-Q"
            },
            {
              "key": "Exhibit",
              "value": "0.2"
            },
            {
              "key": "Filing Date",
              "value": "August 9, 2018"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.26"
            },
            {
              "key": "Description",
              "value": "Purchase Agreement, dated December 20, 2018, by and between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Exhibit",
              "value": "0.1"
            },
            {
              "key": "Filing Date",
              "value": "December 24, 2018"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.27"
            },
            {
              "key": "Description",
              "value": "Eighth Amendment to Office Lease, dated as of March 19, 2019, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Exhibit",
              "value": "0.1"
            },
            {
              "key": "Filing Date",
              "value": "March 22, 2019"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.28"
            },
            {
              "key": "Description",
              "value": "Ninth Amendment to Office Lease, dated May 26, 2022, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C."
            },
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "Exhibit",
              "value": "0.3"
            },
            {
              "key": "Filing Date",
              "value": "August 11, 2022"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 108,
          "title": "Exhibits and Regulatory Filings",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "0.29"
            },
            {
              "key": "Description",
              "value": "Amendment to LLC Purchase Agreement, dated_as of August 31, 2017, by and among _Aptevo_BioTherapeutics LLC, Aptevo"
            },
            {
              "key": "Form",
              "value": "10-Q"
            },
            {
              "key": "Exhibit",
              "value": "0.1"
            },
            {
              "key": "Filing Date",
              "value": "August 9, 2019"
            },
            {
              "key": "File No.",
              "value": "001-37746"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 1,
          "title": "Business Registration and Location Information",
          "data": [
            {
              "key": "Incorporation Jurisdiction",
              "value": "Delaware"
            },
            {
              "key": "IRS Employer Identification No.",
              "value": "81-1567056"
            },
            {
              "key": "Address",
              "value": "2401 4th Avenue, Suite 1050, Seattle, Washington, 98121"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 1,
          "title": "Securities Registration Information",
          "data": [
            {
              "key": "Title of Each Class",
              "value": "Common Stock, $0.001 par value per share"
            },
            {
              "key": "Trading Symbol",
              "value": "APVO"
            },
            {
              "key": "Exchange",
              "value": "The Nasdaq Stock Market LLC (The Nasdaq Capital Market)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 1,
          "title": "Market Overview and Filing Details",
          "data": [
            {
              "key": "Form Type",
              "value": "10-K (Annual Report)"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Commission File Number",
              "value": "001-37746"
            },
            {
              "key": "Aggregate Market Value (as of June 30, 2022)",
              "value": "$18 million"
            },
            {
              "key": "Outstanding Shares (as of March 30, 2023)",
              "value": "7,239,471"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 2,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents from a Form 10-K report, containing 22 items organized into multiple parts. The items range from Business, Risk Factors, and Executive Compensation to Legal Proceedings, Financial Statements, and Exhibits. The document spans pages 23 through 109."
            },
            {
              "key": "Total Items",
              "value": "22"
            },
            {
              "key": "Company",
              "value": "Aptevo Therapeutics Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Other Income (Expense) Overview",
          "data": [
            {
              "key": "Net Other Expense (2022)",
              "value": "$4.0 million"
            },
            {
              "key": "Net Other Expense (2021)",
              "value": "$8.0 million"
            },
            {
              "key": "Decrease Reason",
              "value": "Significant decrease of non-cash interest expenses"
            },
            {
              "key": "Gain on Extinguishment of Liability (2022)",
              "value": "$37.2 million"
            },
            {
              "key": "Gain on Extinguishment of Liability (2021)",
              "value": "$0"
            },
            {
              "key": "Milestone Income (2022)",
              "value": "$2.5 million"
            },
            {
              "key": "Milestone Payment Received (2022)",
              "value": "$10 million net of transaction costs"
            },
            {
              "key": "Income from Discontinued Operations (2022)",
              "value": "$1,013"
            },
            {
              "key": "Income from Discontinued Operations (2021)",
              "value": "$951"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Financial Comparison 2021-2022 Summary",
          "data": [
            {
              "key": "Deferred Payments from Medexus (2022)",
              "value": "$1,013"
            },
            {
              "key": "Deferred Payments from Medexus (2021)",
              "value": "$491"
            },
            {
              "key": "Gain on Contingent Consideration from Saol (2022)",
              "value": "N/A"
            },
            {
              "key": "Gain on Contingent Consideration from Saol (2021)",
              "value": "$460"
            },
            {
              "key": "Total Income from Discontinued Operations (2022)",
              "value": "$1,013"
            },
            {
              "key": "Total Income from Discontinued Operations (2021)",
              "value": "$951"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Income from Discontinued Operations and Cash Flow Summary",
          "data": [
            {
              "key": "Income from Discontinued Operations (2022)",
              "value": "$1.0 million"
            },
            {
              "key": "Income from Discontinued Operations (2021)",
              "value": "$0.5 million"
            },
            {
              "key": "Net cash used in operating activities (2022)",
              "value": "-$21,022,000"
            },
            {
              "key": "Net cash used in operating activities (2021)",
              "value": "-$21,679,000"
            },
            {
              "key": "Net cash used in investing activities (2022)",
              "value": "-$29,000"
            },
            {
              "key": "Net cash used in investing activities (2021)",
              "value": "-$713,000"
            },
            {
              "key": "Net cash used in financing activities (2022)",
              "value": "-$2,616,000"
            },
            {
              "key": "Net cash provided by financing activities (2021)",
              "value": "$26,161,000"
            },
            {
              "key": "Change in cash and cash equivalents (2022)",
              "value": "-$23,667,000"
            },
            {
              "key": "Change in cash and cash equivalents (2021)",
              "value": "$3,769,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 77,
          "title": "Financial Statements",
          "data": [
            {
              "key": "row_1",
              "value": "ancial Statements"
            },
            {
              "key": "row_2",
              "value": "Consolidated Balance Sheets Consolidated Statements of"
            },
            {
              "key": "row_3",
              "value": "Operations"
            },
            {
              "key": "row_4",
              "value": "Consolidated Statements of Cash Flows"
            },
            {
              "key": "row_5",
              "value": "Consolidated Statements of Changes in Stockholders' Equity"
            },
            {
              "key": "summary",
              "value": "This table appears to be a table of contents or index for financial statements, listing the main financial reports including the balance sheets, statements of operations, cash flows, and changes in stockholders' equity. This is typical of the standard set of financial statements found in annual reports or financial filings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Independent Auditor's Report",
          "data": [
            {
              "key": "Document Title",
              "value": "Report of Independent Registered Public Accounting Firm to the Stockholders and the Board of Directors of Aptevo Therapeutics Inc."
            },
            {
              "key": "Company",
              "value": "Aptevo Therapeutics Inc."
            },
            {
              "key": "Financial Statement Dates",
              "value": "As of December 31, 2022 and 2021"
            },
            {
              "key": "Audit Opinion",
              "value": "The consolidated financial statements present fairly, in all material respects, the Company's financial position, results of operations, and cash flows in conformity with GAAP."
            },
            {
              "key": "Basis for Opinion",
              "value": "Audits conducted in accordance with PCAOB standards with an assessment of internal control over financial reporting (without providing an opinion on its effectiveness)."
            },
            {
              "key": "Critical Audit Matter",
              "value": "Liability Related to Sale of Royalties and Other Income – details a royalty purchase agreement with HealthCare Royalty Management, LLC involving an initial receipt of $35 million and potential additional payments based on sales milestones."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 79,
          "title": "Amendment to Royalty Purchase Agreement Gain & Milestone Payments",
          "data": [
            {
              "key": "Transaction Description",
              "value": "Entered into an Amendment to the Royalty Purchase Agreement eliminating ongoing involvement, resulting in derecognition of a liability and recognition of a $37.2 million gain."
            },
            {
              "key": "Gain Recognized",
              "value": "$37.2 million"
            },
            {
              "key": "Milestone Proceeds",
              "value": "$2.5 million credited as other income for 2022"
            },
            {
              "key": "Transaction Date",
              "value": "June 7, 2022"
            },
            {
              "key": "Accounting Methodology",
              "value": "ASC 610-20 Other Income — Gains and Losses from the Derecognition of Nonfinancial Assets using the most likely method"
            },
            {
              "key": "Critical Audit Matter",
              "value": "Significant judgment in accounting treatment led to extensive auditor review, including evaluation of contract documents and mathematical accuracy of management’s gain calculation."
            },
            {
              "key": "Auditor Information",
              "value": "Moss Adams LLP, Seattle, Washington (Audit dated March 30, 2023)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 81,
          "title": "Aptevo Therapeutics Inc. CONSOLIDATED STATEMENTS OF OPERATIONS",
          "data": [
            {
              "key": "Royalty revenue (2022)",
              "value": "3,114"
            },
            {
              "key": "Royalty revenue (2021)",
              "value": "12,292"
            },
            {
              "key": "Research and development (2022)",
              "value": "(17,882)"
            },
            {
              "key": "Research and development (2021)",
              "value": "(18,994)"
            },
            {
              "key": "General and administrative (2022)",
              "value": "(13,873)"
            },
            {
              "key": "General and administrative (2021)",
              "value": "(14,698)"
            },
            {
              "key": "Loss from operations (2022)",
              "value": "(28,641)"
            },
            {
              "key": "Loss from operations (2021)",
              "value": "(21,400)"
            },
            {
              "key": "Other expense from continuing operations, net (2022)",
              "value": "(4,027)"
            },
            {
              "key": "Other expense from continuing operations, net (2021)",
              "value": "(8,008)"
            },
            {
              "key": "Gain on extinguishment of liability related to sale of royalties (2022)",
              "value": "37,182"
            },
            {
              "key": "Gain on extinguishment of liability related to sale of royalties (2021)",
              "value": "—"
            },
            {
              "key": "Milestone income related to sale of royalties (2022)",
              "value": "2,500"
            },
            {
              "key": "Milestone income related to sale of royalties (2021)",
              "value": "="
            },
            {
              "key": "Net income (loss) from continuing operations (2022)",
              "value": "7,014"
            },
            {
              "key": "Net income (loss) from continuing operations (2021)",
              "value": "(29,408)"
            },
            {
              "key": "Income from discontinued operations (2022)",
              "value": "1,013"
            },
            {
              "key": "Income from discontinued operations (2021)",
              "value": "951"
            },
            {
              "key": "Net income (loss) (2022)",
              "value": "8,027"
            },
            {
              "key": "Net income (loss) (2021)",
              "value": "(28,457)"
            },
            {
              "key": "Basic (per share) (2022)",
              "value": "1.57"
            },
            {
              "key": "Basic (per share) (2021)",
              "value": "(6.07)"
            },
            {
              "key": "Diluted (per share) (2022)",
              "value": "1.57"
            },
            {
              "key": "Diluted (per share) (2021)",
              "value": "(6.07)"
            },
            {
              "key": "Basic shares (2022)",
              "value": "5,100,310"
            },
            {
              "key": "Basic shares (2021)",
              "value": "4,687,952"
            },
            {
              "key": "Diluted shares (2022)",
              "value": "5,102,914"
            },
            {
              "key": "Diluted shares (2021)",
              "value": "4,687,952"
            },
            {
              "key": "Summary",
              "value": "This table presents a financial performance comparison between 2022 and 2021. Notable changes include a significant decrease in royalty revenue from 12,292 in 2021 to 3,114 in 2022. However, the company turned around from a net loss of (28,457) in 2021 to a net income of 8,027 in 2022, largely due to a gain of 37,182 from extinguishment of liability related to sale of royalties. Earnings per share improved from (6.07) in 2021 to 1.57 in 2022. The company's share count increased slightly from 2021 to 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Net income (loss) 2022",
              "value": "8027"
            },
            {
              "key": "Net income (loss) 2021",
              "value": "-28457"
            },
            {
              "key": "Stock-based compensation 2022",
              "value": "1802"
            },
            {
              "key": "Stock-based compensation 2021",
              "value": "1643"
            },
            {
              "key": "Depreciation and amortization 2022",
              "value": "901"
            },
            {
              "key": "Depreciation and amortization 2021",
              "value": "1144"
            },
            {
              "key": "Loss on disposal of property and equipment 2022",
              "value": "47"
            },
            {
              "key": "Loss on disposal of property and equipment 2021",
              "value": "4"
            },
            {
              "key": "Non-cash interest expense and other 2022",
              "value": "3239"
            },
            {
              "key": "Non-cash interest expense and other 2021",
              "value": "6642"
            },
            {
              "key": "Gain on extinguishment of liability related to sale of royalties 2022",
              "value": "-37182"
            },
            {
              "key": "Gain on extinguishment of liability related to sale of royalties 2021",
              "value": "null"
            },
            {
              "key": "Net cash used in operating activities 2022",
              "value": "-21022"
            },
            {
              "key": "Net cash used in operating activities 2021",
              "value": "-21679"
            },
            {
              "key": "Purchases of property and equipment 2022",
              "value": "-29"
            },
            {
              "key": "Purchases of property and equipment 2021",
              "value": "-713"
            },
            {
              "key": "Net cash (used in) provided by financing activities 2022",
              "value": "-2616"
            },
            {
              "key": "Net cash (used in) provided by financing activities 2021",
              "value": "26161"
            },
            {
              "key": "Cash, cash equivalents, and restricted cash at end of period 2022",
              "value": "22636"
            },
            {
              "key": "Cash, cash equivalents, and restricted cash at end of period 2021",
              "value": "46303"
            },
            {
              "key": "Change in right-of-use asset and lease liability from lease remeasurement",
              "value": "4372"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 87,
          "title": "Credit Agreement Amendments and Royalty Purchase Agreement Details",
          "data": [
            {
              "key": "Amendment Date",
              "value": "June 7, 2022"
            },
            {
              "key": "Credit Agreement Consent",
              "value": "Limited Consent and Second Amendment"
            },
            {
              "key": "LIBOR Replacement Date",
              "value": "August 30, 2022"
            },
            {
              "key": "New Benchmark",
              "value": "SOFR"
            },
            {
              "key": "Base Interest Rate",
              "value": "6.25% plus SOFR"
            },
            {
              "key": "SOFR Floor",
              "value": "1.50%"
            },
            {
              "key": "SOFR Cap",
              "value": "2.50%"
            },
            {
              "key": "Royalty Payment Received at Closing",
              "value": "$35 million"
            },
            {
              "key": "Potential Additional Payments",
              "value": "up to $32.5 million"
            },
            {
              "key": "2021 Milestone Payment Received",
              "value": "$10 million"
            },
            {
              "key": "June 7, 2022 Amendment Result",
              "value": "Gain of $37.2 million recognized"
            },
            {
              "key": "2022 Milestone Payment Received",
              "value": "$2.5 million"
            },
            {
              "key": "Future Milestone Payment Eligibility",
              "value": "$10 million based on 2023 sales milestones"
            },
            {
              "key": "Revenue Recognition Standard",
              "value": "ASC 606"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 88,
          "title": "Royalty Revenue and Research & Development Expenses",
          "data": [
            {
              "key": "Royalty Revenue Detail",
              "value": "Aptevo’s royalty revenue exclusively related to royalties on Pfizer’s net sales of RUXIENCE. Royalty revenue for the period covered by this report reflects revenue recorded only prior to the second quarter of 2022."
            },
            {
              "key": "Royalty Agreement Amendment",
              "value": "As a result of the Amendment to Royalty Purchase Agreement, we ceased reporting as royalty revenue royalties paid by Pfizer to HCR related to Pfizer’s sales of RUXIENCE."
            },
            {
              "key": "Revenue Recognition Method",
              "value": "Recognized royalty revenue under ASC 606."
            },
            {
              "key": "Collaboration Agreement",
              "value": "Original Collaboration and License Agreement amended in May 2011 to remove exclusivity restrictions for Pfizer's CD20 biosimilar."
            },
            {
              "key": "Future Royalties",
              "value": "Future royalties of 2.5% on any CD20 biosimilar product commercialized by Pfizer."
            },
            {
              "key": "Estimation of Royalty Revenues",
              "value": "Estimated based on historical experience, analyst expectations, and interim data provided by Pfizer."
            },
            {
              "key": "Research and Development Expenses",
              "value": "Expensed as incurred, including internal labor costs and fees to outside service providers."
            },
            {
              "key": "Accrual Estimation Factors",
              "value": "Percentage of work completed, contract milestones for preclinical studies, and number of patients enrolled for clinical studies."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Financial Performance Summary",
          "data": [
            {
              "key": "Net income (loss) from continuing operations (2022)",
              "value": "7014"
            },
            {
              "key": "Net income (loss) from continuing operations (2021)",
              "value": "(29,408)"
            },
            {
              "key": "Income from discontinued operations (2022)",
              "value": "1,013"
            },
            {
              "key": "Income from discontinued operations (2021)",
              "value": "951"
            },
            {
              "key": "Net income (loss) (2022)",
              "value": "8,027"
            },
            {
              "key": "Net income (loss) (2021)",
              "value": "(28,457)"
            },
            {
              "key": "Basic net income (loss) per share from continuing operations (2022)",
              "value": "137"
            },
            {
              "key": "Basic net income (loss) per share from continuing operations (2021)",
              "value": "(6.27)"
            },
            {
              "key": "Diluted net income (loss) per share from continuing operations (2022)",
              "value": "137"
            },
            {
              "key": "Diluted net income (loss) per share from continuing operations (2021)",
              "value": "(6.27)"
            },
            {
              "key": "Basic net income per share from discontinued operations (2022)",
              "value": "0.20"
            },
            {
              "key": "Basic net income per share from discontinued operations (2021)",
              "value": "0.20"
            },
            {
              "key": "Diluted net income per share from discontinued operations (2022)",
              "value": "0.20"
            },
            {
              "key": "Diluted net income per share from discontinued operations (2021)",
              "value": "0.20"
            },
            {
              "key": "Basic shares used in calculation (2022)",
              "value": "5,100,310"
            },
            {
              "key": "Basic shares used in calculation (2021)",
              "value": "4,687,952"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Equity-Based Compensation Instruments Summary",
          "data": [
            {
              "key": "Warrants (2022)",
              "value": "351"
            },
            {
              "key": "Warrants (2021)",
              "value": "351"
            },
            {
              "key": "Outstanding options to purchase common stock (2022)",
              "value": "364"
            },
            {
              "key": "Outstanding options to purchase common stock (2021)",
              "value": "334"
            },
            {
              "key": "Unvested RSUs (2022)",
              "value": "224"
            },
            {
              "key": "Unvested RSUs (2021)",
              "value": "57"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 100,
          "title": "Financial Performance Summary",
          "data": [
            {
              "key": "2022 Net Income",
              "value": "$7,014,000"
            },
            {
              "key": "2021 Net Loss",
              "value": "-$29,408,000"
            },
            {
              "key": "Currency 2022",
              "value": "$"
            },
            {
              "key": "Currency 2021",
              "value": "§"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 105,
          "title": "Exhibits and Financial Statement Schedules",
          "data": [
            {
              "key": "Consolidated Financial Statements",
              "value": "See Index to Consolidated Financial Statements at Item 8 herein."
            },
            {
              "key": "Consolidated Financial Statement Schedules",
              "value": "All schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto."
            },
            {
              "key": "Exhibit Index",
              "value": "103"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 65,
          "title": "PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",
          "data": [
            {
              "key": "Listing Details",
              "value": "Our common stock has been listed on The Nasdaq Capital Market under the symbol “APVO” since October 18, 2019, and was listed on The Nasdaq Global Market from August 1, 2016 to October 17, 2019."
            },
            {
              "key": "Shares Outstanding",
              "value": "7,239,471 shares as of March 30, 2023 held by 115 record holders"
            },
            {
              "key": "Dividend Policy",
              "value": "We have never declared or paid any cash dividends and do not anticipate paying cash dividends for the foreseeable future. Future dividend payments, if any, will be at the discretion of the board of directors, considering our financial condition, operating results, cash needs, and debt instrument restrictions."
            },
            {
              "key": "Recent Sales of Unregistered Securities",
              "value": "No unregistered securities were sold during the year ended December 31, 2022."
            },
            {
              "key": "Issuer Purchases of Equity Securities",
              "value": "No shares of common stock were repurchased during the year ended December 31, 2022."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 27,
          "title": "Capital structure and funding risks",
          "data": [
            {
              "key": "Capital improvements",
              "value": "Investments to improve facilities."
            },
            {
              "key": "Clinical development costs",
              "value": "Costs associated with Phase 1b clinical trial for APVO436 and Phase 1 clinical trial of ALG.APV-527."
            },
            {
              "key": "Macroeconomic concerns",
              "value": "Impact of inflation and cost of capital on funding."
            },
            {
              "key": "Future financing risks",
              "value": "Potential inability to secure financing on reasonable terms."
            },
            {
              "key": "Share issuance details",
              "value": "Future issuances include various agreements and amounts."
            },
            {
              "key": "Covenants from financing",
              "value": "Limitations imposed by debt financing agreements."
            },
            {
              "key": "Dilution risk",
              "value": "Potential dilution of shares through equity fundraising."
            },
            {
              "key": "Macro factors",
              "value": "Economic conditions impacting operations and finances."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 60,
          "title": "Capital Structure and Anti-Takeover Provisions",
          "data": [
            {
              "key": "Preferred Stock Issuance Authorization",
              "value": "The restated certificate of incorporation authorizes issuance of one or more classes or series of preferred stock with specific designations, powers, preferences, and special rights without the need for stockholder approval."
            },
            {
              "key": "Dilution and Impact on Common Stock",
              "value": "The terms of preferred stock, including potential voting rights and dividend preferences, may dilute the voting power or reduce the value of common stock by granting special rights such as director election or veto powers."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Certain provisions in the certificate, the amended and restated by-laws, and rights agreements are designed to discourage, delay, or prevent mergers, acquisitions, and changes in control that could be favorable to stockholders by making it difficult to remove incumbent directors or alter governance."
            },
            {
              "key": "Section 203 of Delaware Law",
              "value": "Section 203 restricts business combinations with interested stockholders, thereby discouraging and delaying changes in control unless carefully approved, with Tang noted as an interested stockholder."
            },
            {
              "key": "Stockholder Rights Agreement",
              "value": "The current short-term rights agreement, recently amended to extend its expiration to November 4, 2023, further complicates and discourages takeover attempts or other changes in control not approved by the Board."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 72,
          "title": "Warrants Public Offering and Liquidity Details",
          "data": [
            {
              "key": "Offering Date",
              "value": "March 11, 2019"
            },
            {
              "key": "Common Stock and Warrants Offering",
              "value": "Public offering of common stock and warrants at a combined price of $14.00 per share; 1,417,857 shares with warrants having a 5-year life and an exercise price of $18.20 per share"
            },
            {
              "key": "Pre-funded Warrants Offering",
              "value": "Pre-funded warrants offered at a combined price of $13.86 per pre-funded warrant; 10-year life to purchase up to 153,571 shares at an exercise price of $0.14; associated related warrants with a 5-year life at $18.20 per share"
            },
            {
              "key": "Exercise Details",
              "value": "Pre-funded warrants were exercised on March 21, 2019; in 2021, warrants with a strike price of $18.20 were exercised resulting in the issuance of 54,105 shares with aggregate proceeds of approximately $1.0 million"
            },
            {
              "key": "Outstanding Warrants",
              "value": "As of December 31, 2022, there were warrants to purchase 350,589 shares of common stock outstanding"
            },
            {
              "key": "Liquidity Overview",
              "value": "Financed operations through various sources including revenue, public offerings, strategic payments, with cash and cash equivalents of $22.6 million and an accumulated deficit of $206.0 million as of December 31, 2022; net cash used in operating activities was $21.0 million for 2022"
            },
            {
              "key": "Future Funding Needs",
              "value": "The Company anticipates continued operating losses and requires additional funding to complete clinical development and eventual commercialization of its product candidates"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 80,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Cash and cash equivalents 2022",
              "value": "22635"
            },
            {
              "key": "Cash and cash equivalents 2021",
              "value": "45044"
            },
            {
              "key": "Restricted cash 2022",
              "value": "0"
            },
            {
              "key": "Restricted cash 2021",
              "value": "1259"
            },
            {
              "key": "Royalty and milestone receivable 2022",
              "value": "2500"
            },
            {
              "key": "Royalty and milestone receivable 2021",
              "value": "3664"
            },
            {
              "key": "Prepaid expenses 2022",
              "value": "1571"
            },
            {
              "key": "Prepaid expenses 2021",
              "value": "1823"
            },
            {
              "key": "Other current assets 2022",
              "value": "744"
            },
            {
              "key": "Other current assets 2021",
              "value": "780"
            },
            {
              "key": "Total current assets 2022",
              "value": "27450"
            },
            {
              "key": "Total current assets 2021",
              "value": "52570"
            },
            {
              "key": "Property and equipment, net 2022",
              "value": "1462"
            },
            {
              "key": "Property and equipment, net 2021",
              "value": "2379"
            },
            {
              "key": "Operating lease right-of-use asset 2022",
              "value": "5303"
            },
            {
              "key": "Operating lease right-of-use asset 2021",
              "value": "1584"
            },
            {
              "key": "Total assets 2022",
              "value": "34215"
            },
            {
              "key": "Total assets 2021",
              "value": "56601"
            },
            {
              "key": "Accounts and other accrued liabilities 2022",
              "value": "3499"
            },
            {
              "key": "Accounts and other accrued liabilities 2021",
              "value": "3462"
            },
            {
              "key": "Accrued compensation 2022",
              "value": "2105"
            },
            {
              "key": "Accrued compensation 2021",
              "value": "2077"
            },
            {
              "key": "Current portion of long-term debt 2022",
              "value": "2000"
            },
            {
              "key": "Current portion of long-term debt 2021",
              "value": "11667"
            },
            {
              "key": "Additional paid-in capital 2022",
              "value": "223962"
            },
            {
              "key": "Additional paid-in capital 2021",
              "value": "215232"
            },
            {
              "key": "Accumulated deficit 2022",
              "value": "-206036"
            },
            {
              "key": "Accumulated deficit 2021",
              "value": "-214063"
            },
            {
              "key": "Total stockholders' equity 2022",
              "value": "17974"
            },
            {
              "key": "Total stockholders' equity 2021",
              "value": "1216"
            },
            {
              "key": "Summary",
              "value": "Total assets decreased from $56,601K in 2021 to $34,215K in 2022; Cash and cash equivalents decreased from $45,044K to $22,635K; Total stockholders' equity improved from $1,216K to $17,974K, mainly due to a reduction in the accumulated deficit and changes in liabilities such as the current portion of long-term debt."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 83,
          "title": "Statement of Stockholders' Equity",
          "data": [
            {
              "key": "Date",
              "value": "December 31, 2020"
            },
            {
              "key": "Total Shares",
              "value": "4,410,909"
            },
            {
              "key": "Total Amount",
              "value": "46"
            },
            {
              "key": "Paid In Capital",
              "value": "202,154"
            },
            {
              "key": "Accumulated Deficit",
              "value": "(185,606)"
            },
            {
              "key": "Stockholders' Equity",
              "value": "16,594"
            },
            {
              "key": "Transaction",
              "value": "Proceeds from exercise of stock options"
            },
            {
              "key": "Shares from Options",
              "value": "26,082"
            },
            {
              "key": "Paid In Capital from Options",
              "value": "218"
            },
            {
              "key": "Stockholders' Equity from Options",
              "value": "218"
            },
            {
              "key": "Transaction",
              "value": "Proceeds from exercise of warrants"
            },
            {
              "key": "Shares from Warrants",
              "value": "54,105"
            },
            {
              "key": "Paid In Capital from Warrants",
              "value": "984"
            },
            {
              "key": "Stockholders' Equity from Warrants",
              "value": "984"
            },
            {
              "key": "Transaction",
              "value": "Proceeds from issuance of common stock"
            },
            {
              "key": "Shares from Issuance",
              "value": "407,047"
            },
            {
              "key": "Total Amount from Issuance",
              "value": "1"
            },
            {
              "key": "Paid In Capital from Issuance",
              "value": "10,233"
            },
            {
              "key": "Stockholders' Equity from Issuance",
              "value": "10,234"
            },
            {
              "key": "Transaction",
              "value": "Stock-based compensation"
            },
            {
              "key": "Paid In Capital from Compensation",
              "value": "1,643"
            },
            {
              "key": "Stockholders' Equity from Compensation",
              "value": "1,643"
            },
            {
              "key": "Transaction",
              "value": "Net loss for the period"
            },
            {
              "key": "Accumulated Deficit from Loss",
              "value": "(28,457)"
            },
            {
              "key": "Stockholders' Equity from Loss",
              "value": "(28,457)"
            },
            {
              "key": "Date",
              "value": "December 31, 2021"
            },
            {
              "key": "Total Shares",
              "value": "4,898,143"
            },
            {
              "key": "Total Amount",
              "value": "47"
            },
            {
              "key": "Paid In Capital",
              "value": "215,232"
            },
            {
              "key": "Accumulated Deficit",
              "value": "(214,063)"
            },
            {
              "key": "Stockholders' Equity",
              "value": "1,216"
            },
            {
              "key": "Transaction",
              "value": "Proceeds from issuance of common stock"
            },
            {
              "key": "Shares from Issuance 2021",
              "value": "1,452,065"
            },
            {
              "key": "Total Amount from Issuance 2021",
              "value": "1"
            },
            {
              "key": "Paid In Capital from Issuance 2021",
              "value": "6,933"
            },
            {
              "key": "Stockholders' Equity from Issuance 2021",
              "value": "6,934"
            },
            {
              "key": "Transaction",
              "value": "Stock-based compensation 2021"
            },
            {
              "key": "Paid In Capital from Compensation 2021",
              "value": "1,802"
            },
            {
              "key": "Stockholders' Equity from Compensation 2021",
              "value": "1,802"
            },
            {
              "key": "Transaction",
              "value": "Net income for the period 2021"
            },
            {
              "key": "Accumulated Deficit from Income 2021",
              "value": "8,027"
            },
            {
              "key": "Stockholders' Equity from Income 2021",
              "value": "8,027"
            },
            {
              "key": "Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Total Shares",
              "value": "6,466,294"
            },
            {
              "key": "Total Amount",
              "value": "48"
            },
            {
              "key": "Paid In Capital",
              "value": "223,962"
            },
            {
              "key": "Accumulated Deficit",
              "value": "(206,036)"
            },
            {
              "key": "Stockholders' Equity",
              "value": "17,974"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 109,
          "title": "Exhibit Index – Financial Filing",
          "data": [
            {
              "key": "Summary",
              "value": "Exhibit index detailing various agreements and amendments related to collaboration and licensing between Wyeth Pharmaceuticals, Trubion Pharmaceuticals, and related successors. The index includes multiple amendments to a Collaboration and License Agreement, a Credit and Security Agreement, an Equity Distribution Agreement, and a Royalty Purchase Agreement, with filings spanning from November 2019 to August 2022."
            },
            {
              "key": "Exhibit Numbers",
              "value": "10.30, 10.31, 10.32, 10.33, 10.34, 10.35, 10.36, 10.37, 10.38, 10.39"
            },
            {
              "key": "Filing Dates",
              "value": "August 14, 2020; November 10, 2019; December 14, 2020; May 11, 2021; August 11, 2022"
            },
            {
              "key": "File Numbers",
              "value": "001-37746, 00 -37746"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 3,
          "title": "Cautionary Note Regarding Forward-Looking Information & Business Overview",
          "data": [
            {
              "key": "Forward-Looking Statements",
              "value": "This section cautions that non-historical statements such as strategy, future operations, clinical trial timing, financial position, revenues, projected costs, prospects, plans, intentions, expectations and objectives may be forward-looking and subject to risks and uncertainties."
            },
            {
              "key": "Identifying Terms",
              "value": "Key terms include 'anticipates', 'believes', 'could', 'designed', 'estimates', 'expects', 'goal', 'intends', 'may', 'plans', 'projects', 'pursuing', 'will', 'would'."
            },
            {
              "key": "Risk Factors Reference",
              "value": "The text refers to factors discussed under 'Risk Factors' and other sections that could cause actual results to differ materially from forward-looking statements."
            },
            {
              "key": "Business Overview",
              "value": "Overview of the company as a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates using ADAPTIR and ADAPTIR-FLEX platform technologies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 10,
          "title": "Complications Associated with Bispecific T Cell Engaging Antibodies",
          "data": [
            {
              "key": "Potential Risks",
              "value": "Systemic Inflammatory Syndrome (CRS)"
            },
            {
              "key": "Symptoms of CRS",
              "value": "Hypotension, hypoxia, uncontrolled systemic inflammatory response, circulatory collapse, vascular leakage, peripheral/pulmonary edema, renal failure, cardiac dysfunction, fatal multiorgan system failure."
            },
            {
              "key": "Other Risk",
              "value": "Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) which shares features with CRS."
            },
            {
              "key": "FDA Designation Date",
              "value": "November 26, 2019"
            },
            {
              "key": "Treatment Options for CRS",
              "value": "Tocilizumab and dexamethasone"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 22,
          "title": "Other Regulation and Human Capital Disclosure",
          "data": [
            {
              "key": "Other Regulation",
              "value": "Our present and future business is subject to various laws and regulations including those related to safe working conditions, laboratory practices, experimental use of animals, and the management of hazardous substances (e.g., radioactive compounds and infectious disease agents) used in product development."
            },
            {
              "key": "Employee Count",
              "value": "45 full-time employees as of December 31, 2022"
            },
            {
              "key": "Office Location",
              "value": "2401 4th Ave., Suite 1050, Seattle, Washington 98121"
            },
            {
              "key": "Telephone Number",
              "value": "(206) 838-0500"
            },
            {
              "key": "Corporate Values",
              "value": "Emphasizes empowerment (acting respectfully, direct communication, and feedback), ownership (focusing on objectives with speed and quality), and professionalism (treating employees as capable adults and justifying bureaucratic tasks)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 25,
          "title": "Risk Factors Summary",
          "data": [
            {
              "key": "Risk of historical losses and future profitability",
              "value": "We have a history of losses and may not be profitable in the future."
            },
            {
              "key": "Dependency on additional capital",
              "value": "We will require additional capital and may be unable to raise capital when needed or on acceptable terms."
            },
            {
              "key": "Talent management risks",
              "value": "Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business."
            },
            {
              "key": "Delays in clinical trials",
              "value": "If we experience delays or difficulties in the commencement, site initiation, enrollment of patients or completion of our clinical trials, the time to reach critical trial data and receipt of any necessary regulatory approvals could be delayed."
            },
            {
              "key": "Commercialization risks",
              "value": "Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize our product candidates."
            },
            {
              "key": "Collaboration risks",
              "value": "We may not be successful in establishing and maintaining collaborations that leverage our capabilities in pursuit of developing and commercializing our product candidates."
            },
            {
              "key": "Competitive pressures",
              "value": "We face and will continue to face substantial competition and our failure to effectively compete may prevent us from achieving significant market penetration for our product candidates, if approved."
            },
            {
              "key": "Macroeconomic conditions",
              "value": "Our business is affected by macroeconomic conditions, including rising and fluctuating inflation, interest rates, market volatility, economic uncertainty, and supply chain constraints."
            },
            {
              "key": "Intellectual property risks",
              "value": "If we are unable to protect our intellectual proprietary rights, our business could be harmed."
            },
            {
              "key": "COVID-19 impact",
              "value": "The ongoing COVID-19 pandemic, including the identification of new variants of the COVID-19 virus, could adversely impact our business, including our clinical trials."
            },
            {
              "key": "Activist stockholder disruptions",
              "value": "Actions of activist stockholders against us have been and could be disruptive and costly and may cause uncertainty about the strategic direction of our business."
            },
            {
              "key": "Dependency on Pfizer's sales",
              "value": "Our future cash flow will depend, in part, on the ability of Pfizer to successfully sell RUXIENCE and our receipt of milestone payments from HCR in connection therewith."
            },
            {
              "key": "FDA compliance risks",
              "value": "The results of our current and planned preclinical studies and clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities."
            },
            {
              "key": "Predictability of trial results",
              "value": "Results from early-preclinical studies and clinical trials may not be predictive of results from later-stage or other trials and interim or top line data may be subject to change or qualification based on the complete analysis of data."
            },
            {
              "key": "Serious adverse events",
              "value": "Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 26,
          "title": "Risks Related to Our Business",
          "data": [
            {
              "key": "Reliance on third parties",
              "value": "Dependence on third parties to conduct clinical and non-clinical trials. Non-compliance may harm our business."
            },
            {
              "key": "Stock price volatility",
              "value": "Volatility of common stock and risk of delisting from Nasdaq, affecting liquidity."
            },
            {
              "key": "Litigation risks",
              "value": "Possible periodic litigation could lead to losses and resource expenditure."
            },
            {
              "key": "History of losses",
              "value": "Significant operating losses in the past, potential future unprofitability."
            },
            {
              "key": "Net income and losses",
              "value": "2022 net income of $8.0 million due to a one-time gain. 2021 net loss of $28.5 million."
            },
            {
              "key": "Accumulated deficit",
              "value": "An accumulated deficit of $206.0 million as of December 31, 2022."
            },
            {
              "key": "Liquidity",
              "value": "Existing cash and deferred payment streams expected to meet cash requirements for the next 12 months."
            },
            {
              "key": "Future funding requirements",
              "value": "Need for additional capital for ongoing development and marketing, with risks of securing funding."
            },
            {
              "key": "Capital requirement factors",
              "value": "Future capital needs depend on milestone payments, product investments, and compliance with payment obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 28,
          "title": "Risk Factors: Macroeconomic and Banking Sector Uncertainties",
          "data": [
            {
              "key": "global_financial_conditions",
              "value": "Uncertainties due to current and future conditions in global financial markets impacting business operations."
            },
            {
              "key": "inflation_impact",
              "value": "Inflation has increased labor costs through higher wages and interest rates, and raised operating costs."
            },
            {
              "key": "supply_chain_constraints",
              "value": "Supply chain constraints have contributed to higher inflation, potentially affecting product development and operations."
            },
            {
              "key": "interest_rate_and_liquidity",
              "value": "Higher interest rates, credit market liquidity issues, and volatility in capital markets may affect capital raising and operations."
            },
            {
              "key": "banking_sector_risks",
              "value": "Events like the failure of Silicon Valley Bank (SVB) and Signature Bank highlight vulnerabilities, legal uncertainties, and contagion risks in the banking sector."
            },
            {
              "key": "us_economic_conditions",
              "value": "The U.S. economy faces risks such as recessions, supply constraints, rising inflation, restricted credit, and potential sovereign credit downgrades."
            },
            {
              "key": "activist_influence",
              "value": "Actions by activist stockholders, including proxy contests, may disrupt strategic direction and incur significant legal and administrative costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Risk Factors Related to Commercialization and Future Cash Flow",
          "data": [
            {
              "key": "Context",
              "value": "Additional costs and stock price fluctuations due to Medexus and commercialization efforts."
            },
            {
              "key": "Dependency",
              "value": "Company's income relies on Medexus's success in commercialization of IXINITY."
            },
            {
              "key": "Milestones",
              "value": "Potential payments based on regulatory and commercial milestones."
            },
            {
              "key": "Royalty Rate",
              "value": "Royalty rate increased from 2% to 5% as of June 30, 2022."
            },
            {
              "key": "External Factors",
              "value": "Potential impacts on future payments from Medexus due to macroeconomic conditions."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Ongoing pandemic may cause delays and affect marketing efforts."
            },
            {
              "key": "RUXIENCE Dependence",
              "value": "Future cash flow dependent on Pfizer's sales of RUXIENCE and related milestone payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Royalty Purchase Agreement Transaction and Associated Risks",
          "data": [
            {
              "key": "Agreement Date",
              "value": "March 30, 2021"
            },
            {
              "key": "Transaction Description",
              "value": "Entered into and closed a Royalty Purchase Agreement with HCR selling the right to receive royalty payments from Pfizer for net sales of RUXIENCE."
            },
            {
              "key": "Initial Payment",
              "value": "$35 million received at closing"
            },
            {
              "key": "Additional Payments Potential",
              "value": "Eligible for up to $32.5 million in milestone payments based on sales achievements in 2021, 2022, and 2023"
            },
            {
              "key": "2021 Milestone Payment",
              "value": "$10 million received on March 8, 2022"
            },
            {
              "key": "2022 Amendment",
              "value": "On June 7, 2022, amended the Agreement to forego 50% of incremental RUXIENCE royalty revenue after HCR reaches 190% of the Investment and Milestone Amounts"
            },
            {
              "key": "2022 Milestone Payment",
              "value": "$2.5 million received on February 28, 2023, recorded as other income"
            },
            {
              "key": "Future Payment Opportunity",
              "value": "Additional milestone payment of $10 million based on 2023 sales milestones"
            },
            {
              "key": "Risk Factors",
              "value": "Dependence on Pfizer's ability to generate net sales, potential disputes or litigation in case of HCR breach, and significant product liability exposure that could result in litigation, adverse publicity and financial liabilities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Risk Factors Impacting Business Operations",
          "data": [
            {
              "key": "Insurance Adequacy",
              "value": "The current amount of insurance may not be adequate to cover all potential liabilities, and obtaining additional product liability insurance may be difficult and expensive."
            },
            {
              "key": "Litigation Risk",
              "value": "Defending product liability litigation or other proceedings could be costly and may have a material adverse effect on the business even if resolved favorably."
            },
            {
              "key": "Key Personnel Retention",
              "value": "Failure to attract, motivate, and retain key personnel, especially senior management, could materially harm the business and affect the ability to implement its strategy."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Ongoing disruptions caused by the COVID-19 pandemic, including new variants, could adversely affect clinical trials, supply chains, financing, and overall business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Tax Attributes and Section 382 Study – Potential Risks",
          "data": [
            {
              "key": "Annual Limitation Calculation",
              "value": "Equal to the outstanding stock value immediately before the ownership change multiplied by the long-term tax-exempt rate (0.89% for November 2020)"
            },
            {
              "key": "Net Operating Loss Carryforwards",
              "value": "$156.2 million federal and $71.1 million state NOL carryforwards as of December 31, 2022, expiring in 2037"
            },
            {
              "key": "Ownership Change Details",
              "value": "Ownership changes in November and December 2020; $162.6 million of NOL carryforwards subject to annual limitation"
            },
            {
              "key": "Research & Development Expenditures",
              "value": "Change under TCJA required capitalization and amortization over five or fifteen years starting 2022"
            },
            {
              "key": "Risk Implications",
              "value": "Limitations on tax attributes, potential future ownership changes, and adjustments in R&D deduction could adversely affect future income tax liabilities and financial condition"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 34,
          "title": "Product Development Risks in Clinical Trials",
          "data": [
            {
              "key": "Clinical Trial Phases",
              "value": "Phase 1b clinical trial with APVO436 and first-in-human Phase 1 clinical study of ALG.APV-527; other candidates have not entered clinical development"
            },
            {
              "key": "Regulatory Concerns",
              "value": "FDA and non-U.S. regulatory authorities may require additional clinical or preclinical studies; early trial results may not predict final outcomes"
            },
            {
              "key": "Interim Data Limitations",
              "value": "Top line or interim data are preliminary and subject to change upon comprehensive analysis"
            },
            {
              "key": "Study Design Limitations",
              "value": "Open-label trial design may lead to patient and investigator bias influencing perceived outcomes"
            },
            {
              "key": "Risk of Clinical Failure",
              "value": "Clinical failure is possible at any stage; past performance in early studies does not guarantee success in later-stage trials"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Clinical Trial and Regulatory Risk Factors",
          "data": [
            {
              "key": "Clinical endpoint uncertainty",
              "value": "Endpoint for a trial does not guarantee that additional co-primary or secondary endpoints will be achieved."
            },
            {
              "key": "Regulatory acceptance risk",
              "value": "Regulatory agencies and IRBs may not accept our assumptions and interpretations, potentially impacting approvability and commercialization."
            },
            {
              "key": "Disclosure judgment risk",
              "value": "Disclosures regarding clinical study details are based on our internal judgment which may not align with external expectations."
            },
            {
              "key": "Clinical trial success risk",
              "value": "Future clinical trials may not be successful and flaws in trials might emerge only in advanced stages."
            },
            {
              "key": "Operational and financial risk",
              "value": "Delays in trial initiation, contract negotiations, additional testing requirements, increased trial costs, and potential funding shortfalls could delay or prevent marketing approval."
            },
            {
              "key": "Manufacturing and supply risk",
              "value": "Issues with the supply or quality of product candidates and materials, and manufacturing process concerns might affect trial execution and future commercial supply."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 36,
          "title": "Regulatory Risks Impacting Clinical Trials and Product Approvals",
          "data": [
            {
              "key": "Regulatory Approval Challenges",
              "value": "The FDA and other non-U.S. regulatory authorities may decline to approve the BLA for various reasons, such as insufficient clinical benefit, safety concerns, or issues with trial design and data interpretation, regardless of advisory committee recommendations."
            },
            {
              "key": "IND and Trial Initiation Delays",
              "value": "There are concerns that delays in filing INDs or IND amendments, manufacturing setbacks, or difficulties with IND-enabling studies could postpone the initiation or continuation of clinical trials."
            },
            {
              "key": "Patient Enrollment Issues",
              "value": "Challenges in locating, enrolling, and retaining a sufficient number of eligible patients for clinical trials, compounded by strict eligibility criteria and competitive trials, may delay achieving critical trial data."
            },
            {
              "key": "Impact of External Factors",
              "value": "Factors such as changing regulatory requirements, potential post-marketing trial conditions, and global issues like the COVID-19 pandemic could further affect the timely progression and commercialization of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 37,
          "title": "Clinical Trial and Product Candidate Risks",
          "data": [
            {
              "key": "ClinicalTrialSiteAvailability",
              "value": "The document highlights issues related to the reporting of preliminary results, proximity, and availability of clinical trial sites which may limit patient and investigator participation."
            },
            {
              "key": "PatientEnrollment",
              "value": "There's concern that the inability to enroll a sufficient number of patients could lead to significant delays or force the abandonment of clinical trials."
            },
            {
              "key": "DevelopmentCostAndDelay",
              "value": "Site initiation and enrollment delays may increase development costs and postpone the availability of both preliminary and final clinical trial results, potentially delaying commercial launch."
            },
            {
              "key": "AdverseEventsAndSideEffects",
              "value": "The text discusses the risks of serious adverse events, undesirable side effects, or other unexpected properties of product candidates that could lead regulatory authorities to suspend trials or impose restrictions."
            },
            {
              "key": "RegulatoryApprovalRisk",
              "value": "There is a risk that serious adverse events or unexpected side effects could result in regulatory actions such as clinical holds, additional warnings, or even denial of approval."
            },
            {
              "key": "CombinationTherapyRisks",
              "value": "The document also notes the uncertainty surrounding the use of product candidates in combination with other therapies, which may lead to additional or more severe side effects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 39,
          "title": "Risks Associated with Third-Party Relationships and Manufacturing Capabilities",
          "data": [
            {
              "key": "Third-party risks",
              "value": "Failure of third parties to perform their contractual duties may lead to delays or termination of clinical trials."
            },
            {
              "key": "Regulatory approval",
              "value": "Challenges in obtaining regulatory approvals if third parties do not fulfill their obligations."
            },
            {
              "key": "Manufacturing dependencies",
              "value": "Dependence on a limited number of third-party manufacturers for production of product candidates."
            },
            {
              "key": "Production delays",
              "value": "Delays in production could affect product availability and clinical development timeline."
            },
            {
              "key": "Alternative arrangements",
              "value": "Difficulty in establishing new manufacturing relationships could lead to market entry delays."
            },
            {
              "key": "Impact of natural disasters",
              "value": "Manufacturing facilities may be affected by natural disasters, leading to potential supply issues."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Risk Factors Related to Manufacturing and Supply Chain Issues",
          "data": [
            {
              "key": "Supply Chain Risks",
              "value": "Challenges in obtaining adequate supplies of product candidates and components used for manufacturing."
            },
            {
              "key": "Third-Party Manufacturer Dependence",
              "value": "Dependence on third-party manufacturers for raw materials and production."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Supply shortages and production timeline disruptions due to the pandemic."
            },
            {
              "key": "Regulatory Approval Requirements",
              "value": "New manufacturers may require FDA approvals, affecting timelines."
            },
            {
              "key": "Production Consistency",
              "value": "Importance of compliance with manufacturing processes to avoid product failures."
            },
            {
              "key": "Potential Cost Increases",
              "value": "Changes in manufacturing or formulation may lead to added costs."
            },
            {
              "key": "Market Constraints",
              "value": "Shortages occurring due to market constraints and competition."
            },
            {
              "key": "Impact on Future Revenues",
              "value": "Changes and delays in manufacturing could limit future revenues and growth."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Risk Factor: Third-Party Manufacturing and Regulatory Approval Challenges",
          "data": [
            {
              "key": "Risk Description",
              "value": "Failure of our third-party manufacturers to successfully produce materials that meet our specifications and stringent FDA or foreign regulatory requirements could prevent regulatory approval of manufacturing facilities and delay product candidate marketing."
            },
            {
              "key": "Reliance on Third Parties",
              "value": "We depend on third parties for manufacturing clinical trial materials and potential commercial supplies, which exposes us to risks if those manufacturers fail to comply with GMP and regulatory standards."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Manufacturers must adhere to strict FDA and foreign GMP requirements. Non-compliance or inability to obtain/maintain approval can lead to significant delays, additional clinical trials, costly corrective actions, or even product recalls."
            },
            {
              "key": "Impact of Changing Manufacturers",
              "value": "Switching manufacturers may require extensive verification, bridging studies, and additional regulatory approvals, further delaying clinical development and commercialization."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Ongoing effects of the COVID-19 pandemic may exacerbate manufacturing difficulties, potentially affecting production timelines and financial performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 42,
          "title": "FDA Designations and Associated Risks",
          "data": [
            {
              "key": "FDA Designation",
              "value": "Certain product candidates have received orphan drug designation, which may provide periods of marketing exclusivity but offers no guarantee of maintenance or future eligibility."
            },
            {
              "key": "Exclusivity Period",
              "value": "If a product is approved, orphan designation can grant up to 7 years of marketing exclusivity, preventing approval of similar products for the same indication."
            },
            {
              "key": "Revocation Risk",
              "value": "Orphan drug designation may be revoked if the FDA determines that material facts were misstated or omitted, or if the product candidate does not meet the required criteria at the time of submission."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "The company may also seek Breakthrough Therapy designation, which does not guarantee a faster development, review, or approval process despite its potential advantages."
            },
            {
              "key": "Competitive and Regulatory Risks",
              "value": "Even with designations, there are risks such as loss of exclusivity, challenges in assuring sufficient product supply, and potential competition from clinically superior products or multiple sponsors receiving similar designations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 43,
          "title": "FDA Regulatory and Clinical Trial Risks",
          "data": [
            {
              "key": "Platform Designation Uncertainty",
              "value": "Even if product candidates qualify as breakthrough therapies, the FDA may later determine that they no longer meet qualification conditions and may rescind the designation. The platform technologies (ADAPTIR and ADAPTIR-FLEX) might not receive or retain designated status."
            },
            {
              "key": "Expedited Review Limitations",
              "value": "Receiving a platform technology designation does not guarantee a faster development, regulatory review, or approval process, and the FDA may revoke the designation if criteria are no longer met."
            },
            {
              "key": "Foreign Clinical Trials Risks",
              "value": "Clinical trials conducted outside the United States may not be accepted by the FDA or foreign regulatory authorities, potentially necessitating additional, costly, and time-consuming trials, which could delay marketing approval and commercialization."
            },
            {
              "key": "Regulatory Approval Challenges",
              "value": "Non-acceptance of foreign trial data and additional trial requirements could impede revenue growth and the ability to execute the long-term business strategy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 45,
          "title": "Risk Factors in Oncology Market Competition and Healthcare Reform",
          "data": [
            {
              "key": "Competitors",
              "value": "AbbVie Inc., Affimed, Amgen Inc., AnaptysBio, Inc., Astellas Pharma Inc., Bayer AG, Biogen Idec Inc., Boehringer Ingelheim GmbH, Bristol Myers Squibb, Cellectis, Chinook Therapeutics, City of Hope, F-Star Biotechnology Ltd., Genentech Inc. (a subsidiary of F. Hoffmann-La Roche Ltd.), Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline plc, Grifols USA LLC, Harpoon Therapeutics, ImmunoGen, Inc., Immunomedics, Inc., Inhibrx Inc., Innate Pharma, Janssen BioTech Inc., Johnson & Johnson, Kyowa Hakko Kirin Pharma, Macrogenics, Inc., Mustang Bio, Pieris Pharmaceuticals, Inc., ProMab Biotechnologies, Sanofi-Aventis US LLC, Strike Pharma, Takeda Pharmaceuticals U.S.A., Inc., University of Pennsylvania, VenCell Therapeutics, Xencor, Inc., Y-mAbs Therapeutics, Inc., and Zymeworks Biopharmaceuticals, Inc."
            },
            {
              "key": "Market Acceptance Risk",
              "value": "The success of product candidates depends on demonstrating efficacy, safety, ease of administration, and competitive pricing. Failure to achieve adequate market acceptance may adversely affect revenues."
            },
            {
              "key": "Regulatory and Legislative Risks",
              "value": "Product candidates may be subject to unfavorable pricing regulations and third-party reimbursement policies. Legislative changes such as the ACA, Budget Control Act, and related amendments, as well as legal and political challenges, pose significant risks."
            },
            {
              "key": "Competitive Strategy",
              "value": "The company expects to compete based on product efficacy, safety, economic value, and ease of administration against current practice or emerging treatments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Regulatory and Clinical Trial Risks Impacting Product Development",
          "data": [
            {
              "key": "Regulatory Approval",
              "value": "Evolving FDA interpretations may impose more stringent requirements, delaying or complicating the approval process for future biologic products."
            },
            {
              "key": "Clinical Trials",
              "value": "The lengthy, uncertain, and expensive process of conducting adequate clinical trials (including Phase 3) poses a risk, as delays or unfavorable results could prevent marketing approvals."
            },
            {
              "key": "Development Costs",
              "value": "Delays in testing or obtaining regulatory approvals are expected to increase product candidate development costs and may necessitate additional funding."
            },
            {
              "key": "Product Viability",
              "value": "Any failure to demonstrate safety and efficacy in clinical trials can lead to termination of product candidates or restrictions that impair commercialization."
            },
            {
              "key": "Competitive Advantage",
              "value": "Any setback or delay in clinical trials could shorten exclusive commercialization periods, allowing competitors to enter the market sooner."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 48,
          "title": "Clinical and Regulatory Risk Factors for APVO210 Development",
          "data": [
            {
              "key": "Product",
              "value": "APVO210"
            },
            {
              "key": "Study Description",
              "value": "MAD clinical study in healthy volunteers indicating APVO210 may not meet the desired target product profile for future commercialization."
            },
            {
              "key": "Clinical Finding",
              "value": "Evidence of increasing titers of ADA with repeated doses, affecting drug levels."
            },
            {
              "key": "ADA Cause Hypothesis",
              "value": "Linked to the mechanism of action of APVO210 rather than the ADAPTIR platform structure."
            },
            {
              "key": "Regulatory Risks",
              "value": "Challenges in obtaining FDA and foreign regulatory approvals, potential impact of government shutdowns and funding issues on regulatory agencies."
            },
            {
              "key": "Development Risk",
              "value": "Redesign of ADAPTIR components based on prior trials does not guarantee avoidance of ADA occurrence or other clinical setbacks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "Regulatory and Compliance Risks",
          "data": [
            {
              "key": "Regulatory Obligations",
              "value": "The document outlines risks associated with additional regulatory obligations, including new or revised laws, compliance requirements, and enforced standards."
            },
            {
              "key": "Compliance Costs",
              "value": "There is concern that increased cost of compliance with post-approval regulations could adversely affect operating results and financial condition."
            },
            {
              "key": "Healthcare Laws and Enforcement",
              "value": "Risks from federal, state, local, and foreign healthcare laws such as the Anti-Kickback Statute, False Claims Act, HIPAA, and HITECH are highlighted, noting potential penalties and enforcement actions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 51,
          "title": "Regulatory Compliance and Legal Risk Factors",
          "data": [
            {
              "key": "Topic",
              "value": "Compliance risks and regulatory challenges under multiple healthcare laws."
            },
            {
              "key": "Relevant Legislation",
              "value": "Physician Payments Sunshine Act, federal Anti-Kickback Statute, False Claims Act, ACA amendments, and various state, local, and foreign laws."
            },
            {
              "key": "Effective Date",
              "value": "January 1, 2022 (for certain reporting requirements)"
            },
            {
              "key": "Potential Consequences",
              "value": "Significant fines, penalties, legal expenses, exclusion from federal/state healthcare programs, and operational disruptions."
            },
            {
              "key": "Industry Impact",
              "value": "Increased compliance burden and risk of regulatory challenge or litigation for pharmaceutical and healthcare companies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Risks Related to Misconduct and Compliance",
          "data": [
            {
              "key": "Misconduct Risks",
              "value": "Employees, contractors, and consultants may engage in misconduct or improper activities."
            },
            {
              "key": "Potential Regulatory Impact",
              "value": "Misconduct could result in regulatory sanctions and harm to reputation."
            },
            {
              "key": "False Claims Act Exposure",
              "value": "Whistleblower cases may result in significant settlements and legal costs."
            },
            {
              "key": "Environmental and Safety Compliance Risks",
              "value": "Operations require compliance with hazardous materials regulations, with potential liabilities."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Inadequate protection of intellectual property could harm business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 54,
          "title": "Risk Factors – Trademarks, Biosimilars, and Patent Litigation",
          "data": [
            {
              "key": "Trademark Protection Risk",
              "value": "Failure to acquire and protect trademarks (e.g., Aptevo logo, ADAPTIR, ADAPTIR-FLEX) could harm the ability to market and sell products and build brand recognition."
            },
            {
              "key": "Biosimilar Competition",
              "value": "Regulatory pathways such as the BPCIA in the U.S. and similar procedures in the EU create exclusivity periods, but uncertainties and potential legislative changes could allow biosimilar competition sooner than anticipated."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "The complex and evolving interpretation of laws like the BPCIA and related EU regulations introduces risk regarding the effectiveness and duration of market or data exclusivity."
            },
            {
              "key": "Patent Infringement Risk",
              "value": "There is a risk of patent infringement claims by third parties, which could result in costly litigation, delays, or even stoppage of product development, manufacturing, or sales."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "Risk Factors: Indemnification Obligations and Stock Price Volatility",
          "data": [
            {
              "key": "Indemnification Obligations",
              "value": "The document discusses mutual indemnification arrangements with Emergent as part of the separation agreement. These indemnities are uncapped and could force the company to divert cash from its operations, exposing it to significant liabilities."
            },
            {
              "key": "Liability Risks",
              "value": "Indemnities related to tax-free distribution and other liabilities may not be fully covered, and third parties could hold the company responsible, leading to potentially large losses that negatively impact the business."
            },
            {
              "key": "Stock Price Volatility",
              "value": "The company’s common stock has experienced extreme volatility, with historical closing prices ranging from $2.00 to $83.16 per share. This volatility is attributed to market dynamics, geopolitical issues (such as the war in Ukraine), and macroeconomic conditions like inflation and fluctuating interest rates."
            },
            {
              "key": "Market and Geopolitical Factors",
              "value": "The document highlights that external factors including the competitive market conditions, investor perceptions, and global events may significantly affect stock performance, independent of the company’s operational results."
            },
            {
              "key": "Financial Impact",
              "value": "The risk events described could have a material and negative effect on the company’s business, results of operations, and overall financial condition."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risk Factors Disclosure: Financial and Operational Risks",
          "data": [
            {
              "key": "Future Milestone Payments",
              "value": "Uncertainty regarding the receipt and extent of future milestone payments under the Amendment to Royalty Purchase Agreement with HCR."
            },
            {
              "key": "Cash Flow Variability",
              "value": "Potential actual or anticipated variations in cash flows and results of operations driven by external factors."
            },
            {
              "key": "Comparative Company Performance",
              "value": "Risk related to the operating and stock price performance of comparable companies."
            },
            {
              "key": "Global Health Challenges",
              "value": "Impact of the ongoing COVID-19 pandemic or similar global health challenges on business operations."
            },
            {
              "key": "Regulatory Approval Delays",
              "value": "Risk of significant stock price decline if FDA or foreign regulatory approval for product candidates is delayed or unfavorable."
            },
            {
              "key": "Litigation Risks",
              "value": "Exposure to securities class action lawsuits and substantial legal costs arising from significant stock price drops."
            },
            {
              "key": "Directors' and Officers' Liability Insurance",
              "value": "Risks associated with reduction or termination of directors' and officers' liability insurance coverage due to events such as an ownership change, leading to heightened indemnification obligations."
            },
            {
              "key": "Internal Controls and SOX Compliance",
              "value": "Increased costs and potential harm to business if effective internal controls are not maintained, particularly under the requirements of Sarbanes-Oxley Act Section 404."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 59,
          "title": "Risk Factors Impacting Stock Price and Regulatory Compliance",
          "data": [
            {
              "key": "Internal Control Weaknesses",
              "value": "Failure of internal control over financial reporting may harm operations, financial results, and reputation; could result in adverse opinions from external auditors."
            },
            {
              "key": "Regulatory Investigations and Sanctions",
              "value": "Potential sanctions or investigations by the SEC or other regulatory authorities if material weaknesses are detected."
            },
            {
              "key": "Market Price Volatility",
              "value": "Announcements related to clinical trial data or product pipeline developments have caused and may cause significant stock price volatility."
            },
            {
              "key": "Delisting Risk",
              "value": "Non-compliance with Nasdaq listing requirements, including minimum stockholders’ equity, could lead to delisting, adversely affecting stock liquidity and market price."
            },
            {
              "key": "Equity Dilution",
              "value": "Future equity issuances, convertible securities, and employee stock awards may dilute existing ownership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 63,
          "title": "Risk of Share Sales Affecting Stock Price",
          "data": [
            {
              "key": "Issue",
              "value": "A significant portion of our shares may be sold into the market at any time, potentially depressing our stock price."
            },
            {
              "key": "Market Impact",
              "value": "If stockholders sell a substantial number of common shares, the market price could decline."
            },
            {
              "key": "Lincoln Park Transaction",
              "value": "In connection with the transaction with Lincoln Park, we registered the resale of shares under the Securities Act of 1933, which may further impact the stock price."
            },
            {
              "key": "Perception Risk",
              "value": "Any perception that such sales may occur could decrease the market price of our common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 73,
          "title": "Risk Factors Related to Pandemic, Macroeconomic Environment, and Future Funding",
          "data": [
            {
              "key": "COVID-19 Impact",
              "value": "The ongoing COVID-19 pandemic, including the emergence of new variants, may cause delays in partnering opportunities and affect the commercialization of IXINITY and RUXIENCE."
            },
            {
              "key": "Macroeconomic Factors",
              "value": "Rising and fluctuating inflation, interest rates, and supply chain constraints could impact milestone payments, deferred payments, and overall strategic partnerships."
            },
            {
              "key": "Deferred Payments & Milestones",
              "value": "There may be potential impacts on future deferred payments and milestones from Medexus and HCR due to macroeconomic conditions and the pandemic effects."
            },
            {
              "key": "Future Funding and Operational Risks",
              "value": "Numerous risks including delayed clinical trials, regulatory approvals, and challenges in raising additional capital among other uncertainties that affect research, development, and commercialization efforts."
            },
            {
              "key": "Cash Resources Outlook",
              "value": "Existing cash, milestone payments related to various agreements, and future deferred payments are projected to be sufficient for meeting operating requirements and debt service for at least twelve months."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 74,
          "title": "Risk Factors and Contractual Obligations",
          "data": [
            {
              "key": "Capital Raising Risk",
              "value": "If the company is unable to raise substantial additional capital on acceptable terms within the next year, it may need to delay, limit, reduce, or terminate its clinical trials and other development or commercialization activities. Raising funds through equity or debt could lead to stock dilution or restrictive covenants."
            },
            {
              "key": "Contractual Obligations",
              "value": "The document outlines significant contractual commitments including an amended operating lease for office and laboratory space in Seattle and a Credit Agreement with MidCap Financial. The Credit Agreement features terms such as an available borrowing capacity of up to $25 million, amendments reducing the principal outstanding, interest adjustments from LIBOR to SOFR, and milestone payment requirements under a license agreement."
            },
            {
              "key": "Pandemic Impact",
              "value": "Ongoing COVID-19 challenges, including potential new variants, may cause delays in clinical trials, non-clinical work, and impact opportunities for partnering product candidates."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 16,
          "title": "Clinical Trial Regulations and Safety Requirements",
          "data": [
            {
              "key": "Pediatric Research Equity Act of 2003",
              "value": "BLAs and supplements for new active ingredients must contain pediatric safety and efficacy data."
            },
            {
              "key": "Good Clinical Practice (GCP)",
              "value": "All phases of clinical studies must comply with GCP standards."
            },
            {
              "key": "Informed Consent",
              "value": "Research subjects must provide written informed consent for participation."
            },
            {
              "key": "Institutional Review Board (IRB)",
              "value": "IRB must review and approve clinical trial plans and informed consent forms."
            },
            {
              "key": "IND Submission Requirements",
              "value": "Each new clinical protocol and amendments must be submitted to the FDA and IRB."
            },
            {
              "key": "Safety Reporting",
              "value": "Sponsors must submit IND safety reports and notify the FDA of any serious adverse reactions."
            },
            {
              "key": "Public Disclosure",
              "value": "Information about trials must be submitted to NIH for dissemination."
            },
            {
              "key": "Manufacturing Regulations",
              "value": "Investigational biologics must comply with cGMP requirements."
            },
            {
              "key": "Discontinuation of Trials",
              "value": "FDA or IRB can order discontinuation of trials that do not comply with regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 68,
          "title": "Royalty Purchase Agreement Amendment and R&D Expenses Summary",
          "data": [
            {
              "key": "Gain from Royalty Agreement Amendment",
              "value": "$37.2 million"
            },
            {
              "key": "Milestone Payment Received",
              "value": "$2.5 million"
            },
            {
              "key": "Expected Additional Milestone Payment",
              "value": "$10 million"
            },
            {
              "key": "R&D Expenses 2022",
              "value": "$17.9 million"
            },
            {
              "key": "R&D Expenses 2021",
              "value": "$19.0 million"
            },
            {
              "key": "Decrease in R&D Expenses",
              "value": "$1.1 million"
            },
            {
              "key": "G&A Expenses 2022",
              "value": "$13.9 million"
            },
            {
              "key": "G&A Expenses 2021",
              "value": "$14.7 million"
            },
            {
              "key": "Decrease in G&A Expenses",
              "value": "$0.8 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 101,
          "title": "Deferred Tax Assets and Liabilities Breakdown",
          "data": [
            {
              "key": "Federal losses carryforward 2022",
              "value": "32,793"
            },
            {
              "key": "Federal losses carryforward 2021",
              "value": "33,520"
            },
            {
              "key": "Capitalized research expenditures 2022",
              "value": "3,361"
            },
            {
              "key": "Capitalized research expenditures 2021",
              "value": "0"
            },
            {
              "key": "Intangible assets 2022",
              "value": "95"
            },
            {
              "key": "Intangible assets 2021",
              "value": "235"
            },
            {
              "key": "Stock-based compensation 2022",
              "value": "912"
            },
            {
              "key": "Stock-based compensation 2021",
              "value": "986"
            },
            {
              "key": "State losses carryforward 2022",
              "value": "3,799"
            },
            {
              "key": "State losses carryforward 2021",
              "value": "3,743"
            },
            {
              "key": "Other deferred tax assets 2022",
              "value": "496"
            },
            {
              "key": "Other deferred tax assets 2021",
              "value": "2,023"
            },
            {
              "key": "Other tax credits 2022",
              "value": "4,852"
            },
            {
              "key": "Other tax credits 2021",
              "value": "3,253"
            },
            {
              "key": "Lease Liabilities 2022",
              "value": "1,371"
            },
            {
              "key": "Lease Liabilities 2021",
              "value": "496"
            },
            {
              "key": "Fixed Assets 2022",
              "value": "442"
            },
            {
              "key": "Fixed Assets 2021",
              "value": "456"
            },
            {
              "key": "Gain related to sale of future royalties 2022",
              "value": "2,016"
            },
            {
              "key": "Gain related to sale of future royalties 2021",
              "value": "5,866"
            },
            {
              "key": "Deferred tax assets, gross 2022",
              "value": "50,237"
            },
            {
              "key": "Deferred tax assets, gross 2021",
              "value": "50,578"
            },
            {
              "key": "Valuation allowance 2022",
              "value": "-49,113"
            },
            {
              "key": "Valuation allowance 2021",
              "value": "-50,245"
            },
            {
              "key": "Deferred tax assets, net of valuation 2022",
              "value": "1,124"
            },
            {
              "key": "Deferred tax assets, net of valuation 2021",
              "value": "333"
            },
            {
              "key": "ROU Assets 2022",
              "value": "-1,124"
            },
            {
              "key": "ROU Assets 2021",
              "value": "-333"
            },
            {
              "key": "Deferred tax liability 2022",
              "value": "-1,124"
            },
            {
              "key": "Deferred tax liability 2021",
              "value": "-333"
            },
            {
              "key": "Net deferred tax assets 2022",
              "value": "0"
            },
            {
              "key": "Net deferred tax assets 2021",
              "value": "0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 102,
          "title": "Federal Tax Rate Reconciliation",
          "data": [
            {
              "key": "Federal tax at statutory rates",
              "value": "21.0%"
            },
            {
              "key": "State taxes, net of federal benefit",
              "value": "-1.8%"
            },
            {
              "key": "Change in valuation allowance",
              "value": "-12.5%"
            },
            {
              "key": "Tax credits",
              "value": "-15.3%"
            },
            {
              "key": "Permanent differences",
              "value": "0.8%"
            },
            {
              "key": "Stock-based compensation",
              "value": "10.1%"
            },
            {
              "key": "Other",
              "value": "-2.3%"
            },
            {
              "key": "Total income tax benefit",
              "value": "0.0%"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 11,
          "title": "Competition Analysis and Collaborations",
          "data": [
            {
              "key": "Competition Overview",
              "value": "Intense competition from U.S. and foreign producers of immunotherapeutic products."
            },
            {
              "key": "Specific Competitors",
              "value": "APVO436 competes with CD123 targeting agents like MGD024, IMGN632, and CAR-T therapies."
            },
            {
              "key": "Collaborations with Alligator Bioscience",
              "value": "Collaboration agreement for the development of ALG.APV-527 targeting 4-1BB and 5T4."
            },
            {
              "key": "Clinical Trials",
              "value": "First-in-human study of ALG.APV-527 started in early 2023."
            },
            {
              "key": "Intellectual Property",
              "value": "Joint ownership of IP generated from collaboration activities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 14,
          "title": "Regulation Impact on Product Development",
          "data": [
            {
              "key": "Regulatory Environment",
              "value": "Regulations in the United States and other countries significantly impact product development, manufacturing, and marketing activities."
            },
            {
              "key": "FDA Regulation",
              "value": "The FDA regulates biopharmaceutical products under the FDCA and PHSA."
            },
            {
              "key": "Compliance Requirements",
              "value": "Sponsors must comply with price reporting, discounts, and rebate requirements."
            },
            {
              "key": "Preclinical Testing Requirements",
              "value": "Stringent government requirements must be satisfied before testing compounds with therapeutic value on human subjects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 18,
          "title": "Regulatory Approval Process and FDA Conditions Overview",
          "data": [
            {
              "key": "Summary",
              "value": "The text outlines the lengthy regulatory approval process for drugs, emphasizing the significant financial expenditures and multiple factors involved, such as the severity of the disease, alternative treatments, and risks/benefits shown in clinical trials. It details various conditions the FDA may impose upon approval, including Risk Evaluation and Mitigation Strategy (REMS), mandatory labeling updates, restrictions on distribution, and post-approval requirements. The passage also discusses designations like Designated Platform Technology and Breakthrough Therapy, noting their potential to expedite development but not guaranteeing approval, as well as the possibility of revocation of approvals if regulatory standards are not maintained."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 19,
          "title": "Orphan Drugs Regulatory Overview",
          "data": [
            {
              "key": "Regulatory Framework",
              "value": "Orphan Drug Act: Provides criteria and incentives for designating drugs intended to treat rare diseases."
            },
            {
              "key": "Designation Criteria",
              "value": "A drug is considered orphan if it treats a rare disease affecting fewer than 200,000 people in the US, or affects more than 200,000 if development costs cannot be recovered from sales."
            },
            {
              "key": "Incentives",
              "value": "Eligibility for special grant funding, potential tax credits, waived user fees, and a seven-year period of market exclusivity after approval."
            },
            {
              "key": "Approved Designation Example",
              "value": "On November 26, 2019, the FDA granted Orphan Drug Designation to APVO436, a bispecific antibody candidate for the treatment of acute myelogenous leukemia (AML)."
            },
            {
              "key": "Clinical Trial Information",
              "value": "APVO436 is currently under evaluation in a Phase 1b clinical trial in patients with AML and MDS."
            },
            {
              "key": "Post-Approval Requirements",
              "value": "Approved biologics are subject to ongoing FDA regulation including record keeping, adverse event reporting, cGMP compliance, and other post-approval conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 20,
          "title": "FDA Regulatory Compliance, Biosimilars, and Patent Litigation Overview",
          "data": [
            {
              "key": "Off-label Promotion Monitoring",
              "value": "The FDA closely monitors advertising and promotional materials to ensure compliance with restrictions on off-label promotion, including adherence to approved package inserts."
            },
            {
              "key": "Enforcement Risks",
              "value": "Non-compliance can lead to significant liabilities such as criminal and civil penalties under the FDCA and False Claims Act, exclusion from federal healthcare programs, and suspension from government contracts."
            },
            {
              "key": "Biosimilars and Exclusivity",
              "value": "Discussion of the Biologics Price Competition and Innovation Act (BPCIA) details the abbreviated approval pathway for biosimilars, criteria for biosimilarity and interchangeability, and related exclusivity periods."
            },
            {
              "key": "Patent Litigation and Protection",
              "value": "The text addresses potential patent infringement lawsuits, patent information exchanges between biosimilar and reference product sponsors, and provisions for patent term restoration."
            },
            {
              "key": "Legislative and Regulatory Updates",
              "value": "References to recent FDA guidance on product importation and legislative provisions in the 2020 Further Consolidated Appropriations Act highlight ongoing regulatory updates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 21,
          "title": "Regulatory Compliance and Clinical Trial Regulation Overview",
          "data": [
            {
              "key": "Extension Calculation",
              "value": "Calculated by adding half of the time from the IND effective date to the initial marketing application submission, plus the full time from submission to approval, adjusted by any period of non-diligence."
            },
            {
              "key": "European Clinical Trials Regulation",
              "value": "CTR EU 536/2014 replaced the CTD with a transition period. Sponsors may use the CTIS for electronic submissions from January 31, 2022, becoming mandatory for new trials from January 31, 2023, and for ongoing trials from January 31, 2025."
            },
            {
              "key": "Healthcare Fraud and Abuse Laws",
              "value": "Describes various federal and state laws, including anti-kickback, false claims, HIPAA, the Physician Payment Sunshine Act, FCPA, the UK Bribery Act, and related regulations affecting drug marketing and reimbursement."
            },
            {
              "key": "Privacy and Security Regulations",
              "value": "Addresses HIPAA and HITECH requirements that impose obligations for the privacy, security, and transmission of individually identifiable health information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 38,
          "title": "Regulatory Risks Related to Clinical Trials and Product Approval",
          "data": [
            {
              "key": "Potential Liabilities",
              "value": "We could be sued and held liable for harm caused to patients."
            },
            {
              "key": "Reputation Risks",
              "value": "Our reputation may suffer due to regulatory challenges."
            },
            {
              "key": "Dependence on Third Parties",
              "value": "We depend on third parties to conduct our clinical and non-clinical trials."
            },
            {
              "key": "Clinical Trial Oversight",
              "value": "Chief Medical Officer provides oversight but we do not have control."
            },
            {
              "key": "Regulatory Responsibilities",
              "value": "Reliance on third-party service providers does not relieve us of regulatory responsibilities."
            },
            {
              "key": "Impact of COVID-19",
              "value": "Business disruptions could negatively affect our clinical trials."
            },
            {
              "key": "Compliance with GCP and GMP",
              "value": "Our clinical trials must comply with GCP and GMP regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 46,
          "title": "Regulatory and Compliance Risks Commentary",
          "data": [
            {
              "key": "Date of Right to Try Act",
              "value": "May 30, 2018"
            },
            {
              "key": "Purpose of Right to Try Act",
              "value": "Provides a federal framework for certain patients to access investigational new drug products."
            },
            {
              "key": "Budget Control Act of 2011 effect",
              "value": "Created measures for spending reductions, affecting Medicare."
            },
            {
              "key": "Effects of legislative changes",
              "value": "Persistent reductions in Medicare payments since April 1, 2013, through 2030."
            },
            {
              "key": "Heightened scrutiny focus",
              "value": "Manufacturers pricing of marketed products."
            },
            {
              "key": "Biden Administration's focus",
              "value": "Health care reform and drug pricing."
            },
            {
              "key": "Risks due to regulatory changes",
              "value": "Could limit federal and state reimbursement for healthcare products."
            },
            {
              "key": "Regulatory Approval Importance",
              "value": "Critical for commercializing product candidates."
            },
            {
              "key": "FDA Requirements",
              "value": "Subject to comprehensive regulation including testing and approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 49,
          "title": "FDA Regulatory Compliance and Products Risks",
          "data": [
            {
              "key": "overview",
              "value": "Risks and potential consequences related to FDA regulatory compliance after product approval."
            },
            {
              "key": "actions_by_FDA",
              "value": "FDA may withdraw approval, impose restrictions, and require post-approval studies."
            },
            {
              "key": "potential_outcomes",
              "value": "Manufacturing restrictions, marketing changes, liability issues, and impact on sales."
            },
            {
              "key": "market_effects",
              "value": "Possibilities of increased costs, delay in revenues, and impact on business and stock price."
            },
            {
              "key": "regulatory_changes",
              "value": "Potential changes in FDA policies and additional laws that could limit marketability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Intellectual Property Risks",
          "data": [
            {
              "key": "Risks of Patent Non-Procurement",
              "value": "May not obtain issued patents."
            },
            {
              "key": "Potential Patent Challenges",
              "value": "Patents may lapse or be challenged."
            },
            {
              "key": "Abandonment of Patent Applications",
              "value": "Potential future abandonment of patents."
            },
            {
              "key": "Impact of Changes in Patent Laws",
              "value": "Changes may diminish intellectual property value."
            },
            {
              "key": "International Patent Protection",
              "value": "Less certain protections outside the USA."
            },
            {
              "key": "Costs of Patent Litigation",
              "value": "Litigation costs can be substantial."
            },
            {
              "key": "Potential Outcomes of Patent Litigation",
              "value": "Outcome may not favor patent holders."
            },
            {
              "key": "Unpredictability of Legal Costs",
              "value": "Intellectual property lawsuits are unpredictable."
            },
            {
              "key": "Participation in Adversarial Proceedings",
              "value": "May participate in proceedings before PTAB or EPO."
            },
            {
              "key": "Impact of Supreme Court Rulings",
              "value": "Recent rulings have narrowed patent protection."
            },
            {
              "key": "Uncertainty in Future Patent Laws",
              "value": "Future laws may weaken patent acquisition or enforcement."
            },
            {
              "key": "Trademark Reliance",
              "value": "Rely on trademarks for brand recognition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 55,
          "title": "Patent Litigation and Intellectual Property Rights",
          "data": [
            {
              "key": "claims",
              "value": "Patent infringement or other claims could prevent product commercialization."
            },
            {
              "key": "patent_litigation",
              "value": "There has been substantial litigation regarding patent rights in the pharmaceutical and biotechnology industries."
            },
            {
              "key": "potential_claims",
              "value": "Claims against the company's trademarks could adversely affect operations."
            },
            {
              "key": "confidentiality",
              "value": "Failure to protect proprietary information could affect technology value."
            },
            {
              "key": "litigation_costs",
              "value": "Patent litigation could absorb significant management time and incur substantial costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 61,
          "title": "Litigation and Regulatory Risks",
          "data": [
            {
              "key": "Forum Selection Clause",
              "value": "The by-laws specify the Court of Chancery in Delaware as the exclusive forum for certain stockholder actions."
            },
            {
              "key": "Litigation Risks",
              "value": "Periodic litigation could result in costs and divert management's attention."
            },
            {
              "key": "Data Protection Compliance",
              "value": "Failure to comply with data protection laws could lead to enforcement actions and significant penalties."
            },
            {
              "key": "GDPR Compliance",
              "value": "The GDPR imposes strict requirements on the handling of personal data."
            },
            {
              "key": "Potential Penalties Under GDPR",
              "value": "Fines up to €20 million or 4% of annual global revenues for non-compliance."
            },
            {
              "key": "Regulatory Variability",
              "value": "Different interpretations of GDPR among EU member states could lead to inconsistencies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 62,
          "title": "Regulatory Risks Related to Data Protection and Privacy Laws",
          "data": [
            {
              "key": "Adverse publicity",
              "value": "Discusses potential impacts from adverse publicity related to regulatory compliance."
            },
            {
              "key": "New regulations",
              "value": "Anticipates new proposed laws and regulations regarding privacy and data protection."
            },
            {
              "key": "Data security risks",
              "value": "Highlights potential vulnerabilities in information technology systems and risks from cyber-security incidents."
            },
            {
              "key": "Impact of breaches",
              "value": "Outlines consequences of data breaches on business operations and reputation."
            },
            {
              "key": "Regulatory compliance costs",
              "value": "Discusses potential costs related to compliance with data protection laws and regulations."
            },
            {
              "key": "COVID-19 impact",
              "value": "Mentions increased security risks due to remote working environments during the pandemic."
            },
            {
              "key": "Consequences of disruptions",
              "value": "Details potential delays and negative impacts on product development due to system disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 64,
          "title": "SEC Filing - Legal Proceedings and Properties",
          "data": [
            {
              "key": "Unresolved Staff Comments",
              "value": "None"
            },
            {
              "key": "Properties",
              "value": "We lease our headquarters office and laboratory space in Seattle, Washington. The Seattle facility is approximately 48,000 square feet and the lease expires in April 2030."
            },
            {
              "key": "Legal Proceedings",
              "value": "We may from time to time be named as a party to legal claims, actions and complaints including issues related to employment claims, intellectual property and other third party claims. Management believes that there are currently no claims or actions pending that could materially affect our operations, financial condition, or cash flows."
            },
            {
              "key": "Mine Safety Disclosures",
              "value": "Not applicable"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 67,
          "title": "Regulatory and Clinical Trial Updates",
          "data": [
            {
              "key": "APVO436 combination therapies",
              "value": "APVO436 was shown to be generally safe and well tolerated when combined with venetoclax and azacitidine."
            },
            {
              "key": "FDA notification",
              "value": "Received 'may proceed' notification from FDA in September 2022 for clinical trials."
            },
            {
              "key": "First-in-human study",
              "value": "Initiated in Q1 2023 with first patient dosed in February 2023."
            },
            {
              "key": "Royalty revenue 2022",
              "value": "Recorded royalty revenue of $3.1 million for 2022."
            },
            {
              "key": "Royalty Purchase Agreement",
              "value": "We sold rights to receive royalty payments from Pfizer concerning net sales of RUXIENCE."
            },
            {
              "key": "Nasdaq compliance matter",
              "value": "Entered into amendment to Royalty Purchase Agreement in June 2022."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": true,
      "elements": [
        {
          "type": "strategic_restructuring",
          "page": 56,
          "title": "Risk Factors Related to Collaborations and Transactions",
          "data": [
            {
              "key": "Collaboration agreement with Alligator",
              "value": "Entered into collaboration agreement in July 2017 to develop ALG.APV-527."
            },
            {
              "key": "Risks of collaboration",
              "value": "Success of collaborations depend on partner's resources and efforts."
            },
            {
              "key": "Impact of COVID-19",
              "value": "Delays in developing product candidates due to pandemic-related factors."
            },
            {
              "key": "Strategic alliances and business combinations",
              "value": "Engaging in discussions for alliances, acquisitions, and joint ventures."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 32,
          "title": "Supply Chain Disruption and Related Financial Risks",
          "data": [
            {
              "key": "Supply Chain Impact",
              "value": "The ongoing COVID-19 pandemic may delay or disrupt supply chain operations if suppliers and manufacturers face difficulties obtaining necessary supplies or prioritize other customers."
            },
            {
              "key": "Quality and Process Changes",
              "value": "Third party manufacturers might implement measures, deviating from typical requirements, potentially affecting product quality and supply consistency."
            },
            {
              "key": "Regulatory Developments",
              "value": "Evolving laws and FDA guidance in response to COVID-19 may require changes to internal processes to ensure compliance."
            },
            {
              "key": "Credit Agreement and Financial Constraints",
              "value": "The document details restrictive covenants within the Credit and Security Agreement that could limit cash flow, increase interest liabilities, and potentially lead to default, thereby compounding business risks."
            },
            {
              "key": "Ownership Change Considerations",
              "value": "Discussion of a Section 382 study indicating an 'ownership change' which can affect tax attributes and financial planning."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 12,
          "title": "Collaboration Agreement and Intellectual Property Protection",
          "data": [
            {
              "key": "Revenue sharing",
              "value": "Percentage of revenue from future commercialization partners or tiered royalties on net sales."
            },
            {
              "key": "Technical criteria",
              "value": "Certain technical criteria or 'stage gates' that affect collaboration."
            },
            {
              "key": "Intellectual property rights",
              "value": "Combination of patents, trademarks, trade secrets to protect proprietary information."
            },
            {
              "key": "Patent management",
              "value": "Filing patent applications for new inventions and meaningful improvements."
            },
            {
              "key": "Patent portfolio",
              "value": "Ownership or exclusive licenses of patents supporting ADAPTIR-FLEX and ADAPTIR platforms."
            },
            {
              "key": "Global patent strategy",
              "value": "Seeking patent protection where markets for products exist."
            },
            {
              "key": "Trade secrets strategy",
              "value": "Retaining proprietary information as trade secrets when beneficial."
            },
            {
              "key": "License agreements",
              "value": "Party to several license agreements with commercial obligations."
            },
            {
              "key": "ADAPTIR Platform Protection",
              "value": "ADAPTIR technology protected via patents and trade secrets."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 23,
          "title": "Diversity, Equity, and Inclusion Initiatives",
          "data": [
            {
              "key": "DEI Commitment",
              "value": "The company is committed to fostering diversity, equity, and inclusion (DEI) within its work environment and beyond as a key element to business growth and innovation."
            },
            {
              "key": "Equal Opportunity Employment",
              "value": "Aptevo is an equal opportunity employer with policies supporting fair treatment, anti-harassment, and anti-retaliation."
            },
            {
              "key": "Female Workforce Percentage",
              "value": "60% of the workforce as of December 31, 2022"
            },
            {
              "key": "Female Leadership Percentage",
              "value": "50% of leadership (Director level and above) as of December 31, 2022"
            },
            {
              "key": "Racial/Ethnic Diversity in Workforce",
              "value": "40% of the workforce is racially or ethnically diverse as of December 31, 2022"
            },
            {
              "key": "Racial/Ethnic Diversity in Leadership",
              "value": "36% of leadership (Director level and above) is racially or ethnically diverse as of December 31, 2022"
            },
            {
              "key": "Recruitment and Retention Practices",
              "value": "The company invests in resources to recruit, develop, and retain talent, emphasizing internal promotion and a supportive work environment."
            },
            {
              "key": "Workforce Strategy",
              "value": "Hybrid working environment with necessary tools to support both onsite and remote employees, ensuring safety and productivity."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 18,
    "EUR": 9,
    "AUD": 8,
    "CAD": 5,
    "INR": 1,
    "ZAR": 2,
    "RUB": 5
  },
  "sha1": "0981826b4b43a88920f3e01c71ae73539bab84cc"
}